false Q3 0000890394 --12-31 Unlimited Unlimited http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member true true P4Y P3Y P4Y P3Y P7Y10M20D P11M23D P3Y10M20D P3Y8M26D P1Y11M12D P7Y10M6D 1.57 15.00 25.60 144.00 410.0 1.57 14.99 25.59 143.99 409.99 924.00 924.00 2023-01-31 2023-10-31 0000890394 2022-01-01 2022-09-30 xbrli:shares 0000890394 2022-11-04 iso4217:USD 0000890394 2022-09-30 0000890394 2021-12-31 0000890394 prso:SeriesASpecialVotingPreferredStockMember 2022-09-30 0000890394 prso:SeriesASpecialVotingPreferredStockMember 2021-12-31 iso4217:USD xbrli:shares 0000890394 2021-01-01 2021-12-31 0000890394 us-gaap:ProductMember 2022-07-01 2022-09-30 0000890394 us-gaap:ProductMember 2021-07-01 2021-09-30 0000890394 us-gaap:ProductMember 2022-01-01 2022-09-30 0000890394 us-gaap:ProductMember 2021-01-01 2021-09-30 0000890394 prso:RoyaltyAndOtherMember 2022-07-01 2022-09-30 0000890394 prso:RoyaltyAndOtherMember 2021-07-01 2021-09-30 0000890394 prso:RoyaltyAndOtherMember 2022-01-01 2022-09-30 0000890394 prso:RoyaltyAndOtherMember 2021-01-01 2021-09-30 0000890394 2022-07-01 2022-09-30 0000890394 2021-07-01 2021-09-30 0000890394 2021-01-01 2021-09-30 0000890394 us-gaap:CommonStockMember 2021-12-31 0000890394 prso:ExchangeableStockMember 2021-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000890394 us-gaap:RetainedEarningsMember 2021-12-31 0000890394 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000890394 prso:ExchangeableStockMember 2022-01-01 2022-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000890394 2022-01-01 2022-03-31 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000890394 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000890394 us-gaap:CommonStockMember 2022-03-31 0000890394 prso:ExchangeableStockMember 2022-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000890394 us-gaap:RetainedEarningsMember 2022-03-31 0000890394 2022-03-31 0000890394 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000890394 2022-04-01 2022-06-30 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000890394 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000890394 us-gaap:CommonStockMember 2022-06-30 0000890394 prso:ExchangeableStockMember 2022-06-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000890394 us-gaap:RetainedEarningsMember 2022-06-30 0000890394 2022-06-30 0000890394 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000890394 prso:ExchangeableStockMember 2022-07-01 2022-09-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000890394 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000890394 us-gaap:CommonStockMember 2022-09-30 0000890394 prso:ExchangeableStockMember 2022-09-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000890394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000890394 us-gaap:RetainedEarningsMember 2022-09-30 0000890394 us-gaap:CommonStockMember 2020-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000890394 us-gaap:RetainedEarningsMember 2020-12-31 0000890394 2020-12-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000890394 2021-01-01 2021-03-31 0000890394 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000890394 us-gaap:CommonStockMember 2021-03-31 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000890394 us-gaap:RetainedEarningsMember 2021-03-31 0000890394 2021-03-31 0000890394 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000890394 2021-04-01 2021-06-30 0000890394 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000890394 us-gaap:CommonStockMember 2021-06-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000890394 us-gaap:RetainedEarningsMember 2021-06-30 0000890394 2021-06-30 0000890394 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000890394 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000890394 us-gaap:CommonStockMember 2021-09-30 0000890394 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000890394 us-gaap:RetainedEarningsMember 2021-09-30 0000890394 2021-09-30 xbrli:pure 0000890394 prso:ScientificResearchAndExperimentalDevelopmentMember 2022-01-01 2022-09-30 0000890394 srt:MinimumMember 2022-01-01 2022-09-30 0000890394 srt:MaximumMember 2022-01-01 2022-09-30 0000890394 us-gaap:DevelopedTechnologyRightsMember 2022-09-30 0000890394 us-gaap:CustomerRelationshipsMember 2022-09-30 0000890394 us-gaap:OtherIntangibleAssetsMember 2022-09-30 0000890394 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000890394 us-gaap:CustomerRelationshipsMember 2021-12-31 0000890394 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0000890394 us-gaap:DevelopedTechnologyRightsMember srt:MinimumMember 2022-01-01 2022-09-30 0000890394 us-gaap:DevelopedTechnologyRightsMember 2022-07-01 2022-09-30 0000890394 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-09-30 0000890394 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0000890394 us-gaap:CustomerRelationshipsMember 2022-07-01 2022-09-30 0000890394 2019-01-01 2019-12-31 0000890394 prso:EscrowSharesExchangeableSharesMember 2022-01-01 2022-09-30 0000890394 prso:EscrowSharesCommonStockMember 2022-01-01 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2021-01-01 2021-09-30 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000890394 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-09-30 0000890394 prso:CommonStockWarrantsMember 2022-01-01 2022-09-30 0000890394 prso:CommonStockWarrantsMember 2021-01-01 2021-09-30 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2022-01-01 2022-09-30 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember prso:FormerSecurityHoldersMember 2022-09-30 0000890394 2021-12-17 0000890394 prso:PerasoSharesMember 2021-12-17 0000890394 prso:EscrowSharesMember 2021-12-17 utr:D 0000890394 2021-12-16 2021-12-17 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2022-09-30 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2021-12-31 0000890394 us-gaap:CommonStockMember prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 us-gaap:WarrantMember prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 prso:ShareBasedAwardsMember prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 prso:PerasoTechMember 2021-12-31 0000890394 prso:PrecombinationServiceShareBasedAwardsMember prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 prso:PerasoTechMember 2021-01-01 2021-12-31 0000890394 us-gaap:CashAndCashEquivalentsMember 2022-09-30 0000890394 us-gaap:ShortTermInvestmentsMember 2022-09-30 0000890394 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000890394 us-gaap:ShortTermInvestmentsMember 2021-12-31 0000890394 prso:LongTermInvestmentsMember 2021-12-31 0000890394 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0000890394 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2021-12-31 0000890394 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2022-01-01 2022-03-31 0000890394 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2022-01-01 2022-09-30 0000890394 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-03-31 0000890394 srt:RestatementAdjustmentMember 2022-01-01 2022-03-31 0000890394 stpr:CA 2022-01-01 2022-09-30 0000890394 prso:WaterlooCanadaMember 2022-01-01 2022-09-30 0000890394 prso:TorontoCanadaMember 2022-01-01 2022-09-30 0000890394 2022-04-13 0000890394 stpr:CA-ON 2022-05-26 0000890394 2022-04-13 2022-04-13 0000890394 stpr:CA-ON 2022-05-26 2022-05-26 0000890394 2022-03-01 prso:Segment 0000890394 srt:NorthAmericaMember 2022-07-01 2022-09-30 0000890394 srt:NorthAmericaMember 2021-07-01 2021-09-30 0000890394 srt:NorthAmericaMember 2022-01-01 2022-09-30 0000890394 srt:NorthAmericaMember 2021-01-01 2021-09-30 0000890394 country:HK 2022-07-01 2022-09-30 0000890394 country:HK 2021-07-01 2021-09-30 0000890394 country:HK 2022-01-01 2022-09-30 0000890394 country:HK 2021-01-01 2021-09-30 0000890394 country:TW 2022-07-01 2022-09-30 0000890394 country:TW 2021-07-01 2021-09-30 0000890394 country:TW 2022-01-01 2022-09-30 0000890394 country:TW 2021-01-01 2021-09-30 0000890394 country:JP 2022-07-01 2022-09-30 0000890394 country:JP 2022-01-01 2022-09-30 0000890394 prso:RestOfWorldMember 2022-07-01 2022-09-30 0000890394 prso:RestOfWorldMember 2021-07-01 2021-09-30 0000890394 prso:RestOfWorldMember 2022-01-01 2022-09-30 0000890394 prso:RestOfWorldMember 2021-01-01 2021-09-30 0000890394 prso:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000890394 prso:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000890394 prso:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000890394 prso:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000890394 prso:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000890394 prso:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000890394 prso:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000890394 prso:CustomerEMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000890394 prso:CustomerEMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2022-01-01 2022-09-30 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2021-01-01 2021-12-31 prso:Customer 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2022-09-30 0000890394 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember prso:MajorCustomersMember 2021-12-31 0000890394 prso:EquityIncentivePlan2010Member 2022-01-01 2022-09-30 0000890394 prso:StockIncentivePlan2019Member 2022-09-30 0000890394 prso:StockIncentivePlan2019Member 2021-11-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember srt:MinimumMember 2022-01-01 2022-09-30 0000890394 prso:StockIncentivePlan2019Member prso:EmployeeAndDirectorsStockOptionsMember srt:MaximumMember 2022-01-01 2022-09-30 0000890394 prso:NewEmployeesMember 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:EmployeeAndDirectorsStockOptionsMember 2021-01-01 2021-09-30 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000890394 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2021-12-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-06-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-09-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-01-01 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-04-01 2022-06-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember 2022-07-01 2022-09-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0000890394 prso:EquityIncentivePlanTwoThousandNineteenMember us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000890394 prso:RangeOfExercisePriceOneMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceTwoMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceThreeMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceFourMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceFiveMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceSixMember prso:EmployeeAndDirectorsStockOptionsMember 2022-01-01 2022-09-30 0000890394 prso:RangeOfExercisePriceOneMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceTwoMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceThreeMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceFourMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceFiveMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:RangeOfExercisePriceSixMember prso:EmployeeAndDirectorsStockOptionsMember 2022-09-30 0000890394 prso:CommonStockOneMember 2022-09-30 0000890394 prso:CommonStockTwoMember 2022-09-30 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-02-05 2021-02-05 iso4217:CAD 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-03-05 2021-03-05 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-09-17 2021-09-17 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2022-01-01 2022-09-30 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2022-09-30 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-08-01 2021-08-31 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-12-16 2021-12-16 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-07-01 2021-09-30 0000890394 prso:ScientificResearchAndExperimentalDevelopmentLoanAgreementMember 2021-01-01 2021-09-30 0000890394 us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000890394 us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000890394 prso:LoanFacilitiesMember 2021-07-01 2021-09-30 0000890394 prso:LoanFacilitiesMember 2021-01-01 2021-09-30 0000890394 prso:ConsultantMember 2022-01-01 2022-09-30 0000890394 prso:ConsultantMember 2021-01-01 2021-09-30 0000890394 prso:EmployedFamilyMemberMember 2022-01-01 2022-09-30 0000890394 prso:EmployedFamilyMemberMember 2021-01-01 2021-09-30 0000890394 prso:TechnologyLicenseAndPatentAssignmentAgreementMember prso:IntelCorporationMember 2022-08-05 2022-08-05 0000890394 prso:TechnologyLicenseAndPatentAssignmentAgreementMember prso:IntelCorporationMember 2022-07-01 2022-09-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

(Mark one)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

 

OR

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                to              

 

Commission file number 000-32929

 

PERASO INC.

(Exact name of registrant as specified in its charter)

 

Delaware

   

77-0291941

(State or other jurisdiction

 

(I.R.S. Employer

of Incorporation or organization)

 

Identification Number)

 

2309 Bering Drive

San Jose, California 95131

(Address of principal executive office and zip code)

 

(408) 418-7500

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading symbol(s)

 

Name of each exchange on which registered

 

Common Stock, par value $0.001 per share

PRSO

The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days.  Yes   NO 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes   NO 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer 

 

Accelerated filer 

Non-accelerated filer 

 

Smaller reporting company 

Emerging growth company 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No 

 

The number of outstanding shares of the registrant’s exchangeable shares, no par value, was 9,111,801 as of November 4, 2022.

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 12,768,987 as of November 4, 2022.

 


 

 

PERASO INC.

 

FORM 10-Q

September 30, 2022

 

TABLE OF CONTENTS

 

PART I —

FINANCIAL INFORMATION

3

 

 

 

Item 1.

Financial Statements (Unaudited):

3

 

 

 

 

Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021

3

 

 

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2022 and 2021

4

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2022 and 2021

5

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021

6

 

 

 

 

Notes to Condensed Consolidated Financial Statements

7

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

 

 

 

Item 4.

Controls and Procedures

34

 

 

 

PART II —

OTHER INFORMATION

34

 

 

 

Item 1.

Legal Proceedings

34

 

 

 

Item 1A.

Risk Factors

34

 

 

 

Item 6.

Exhibits

36

 

 

 

 

Signatures

37

 

 

 

 

 


 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

PERASO INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

 

 

 

September 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

 

(unaudited)

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

2,852

 

 

$

5,893

 

Short-term investments

 

 

1,071

 

 

 

9,267

 

Accounts receivable, net

 

 

1,636

 

 

 

2,436

 

Inventories

 

 

5,271

 

 

 

3,824

 

Tax credits and receivables

 

 

1,076

 

 

 

1,099

 

Deferred cost of net revenue

 

 

600

 

 

 

 

Prepaid expenses and other

 

 

918

 

 

 

1,159

 

Total current assets

 

 

13,424

 

 

 

23,678

 

 

 

 

 

 

 

 

 

 

Long-term investments

 

 

 

 

 

2,928

 

Property and equipment, net

 

 

2,058

 

 

 

2,349

 

Intangible assets, net

 

 

6,803

 

 

 

8,355

 

Goodwill

 

 

9,946

 

 

 

9,946

 

Right-of-use lease asset, net

 

 

1,181

 

 

 

617

 

Other

 

 

129

 

 

 

78

 

Total assets

 

$

33,541

 

 

$

47,951

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,744

 

 

$

1,937

 

Accrued expenses and other

 

 

1,867

 

 

 

2,903

 

Deferred revenue

 

 

219

 

 

 

375

 

Short-term lease liability

 

 

633

 

 

 

379

 

Total current liabilities

 

 

4,463

 

 

 

5,594

 

 

 

 

 

 

 

 

 

 

Long-term lease liability

 

 

554

 

 

 

288

 

Total liabilities

 

 

5,017

 

 

 

5,882

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 6)

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

Preferred stock, $0.01 par value; 20,000 shares authorized

 

 

 

 

 

 

Series A special voting preferred stock, $0.01 par value; one share authorized; and one share issued and outstanding at September 30, 2022 and December 31, 2021, respectively

 

 

 

 

 

 

Common stock, $0.001 par value; 120,000 shares authorized; 12,757 shares and 12,284 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively

 

 

13

 

 

 

12

 

Exchangeable shares, no par value; unlimited shares authorized; 9,112 shares

and 9,295 shares outstanding at September 30, 2022 and December 31, 2021, respectively

 

 

 

 

 

 

Additional paid-in capital

 

 

163,551

 

 

 

159,256

 

Accumulated other comprehensive loss

 

 

(36

)

 

 

 

Accumulated deficit

 

 

(135,004

)

 

 

(117,199

)

Total stockholders’ equity

 

 

28,524

 

 

 

42,069

 

Total liabilities and stockholders’ equity

 

$

33,541

 

 

$

47,951

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


 

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share data)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

$

3,060

 

 

$

1,389

 

 

$

10,384

 

 

$

3,016

 

Royalty and other

 

 

234

 

 

 

629

 

 

 

597

 

 

 

800

 

Total net revenue

 

 

3,294

 

 

 

2,018

 

 

 

10,981

 

 

 

3,816

 

Cost of net revenue

 

 

2,000

 

 

 

919

 

 

 

6,747

 

 

 

1,973

 

Gross profit

 

 

1,294

 

 

 

1,099

 

 

 

4,234

 

 

 

1,843

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

4,509

 

 

 

2,696

 

 

 

15,636

 

 

 

8,375

 

Selling, general and administrative

 

 

3,353

 

 

 

1,746

 

 

 

8,938

 

 

 

4,852

 

Gain on license and asset sale

 

 

(2,557

)

 

 

 

 

 

(2,557

)

 

 

 

Total operating expenses

 

 

5,305

 

 

 

4,442

 

 

 

22,017

 

 

 

13,227

 

Loss from operations

 

 

(4,011

)

 

 

(3,343

)

 

 

(17,783

)

 

 

(11,384

)

Interest expense

 

 

(5

)

 

 

(870

)

 

 

(11

)

 

 

(2,170

)

Other expense, net

 

 

8

 

 

 

392

 

 

 

(11

)

 

 

147

 

Net loss

 

$

(4,008

)

 

$

(3,821

)

 

$

(17,805

)

 

$

(13,407

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive loss, net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net unrealized gain (loss) on available-for-sale securities

 

 

5

 

 

 

 

 

 

(36

)

 

 

 

Comprehensive loss

 

$

(4,003

)

 

$

(3,821

)

 

$

(17,841

)

 

$

(13,407

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.20

)

 

$

(0.73

)

 

$

(0.89

)

 

$

(2.55

)

Shares used in computing net loss per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

20,039

 

 

 

5,258

 

 

 

19,950

 

 

 

5,250

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

4


 

 

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series A Special Voting

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Accumulated Other

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Common Stock

 

 

Exchangeable Shares

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Total

 

Balance as of December 31, 2021

 

 

 

 

$

 

 

 

12,284

 

 

$

12

 

 

 

9,295

 

 

$

 

 

$

159,256

 

 

$

 

 

$

(117,199

)

 

$

42,069

 

Exchange of exchangeable shares

 

 

 

 

 

 

 

 

100

 

 

 

 

 

 

(100

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under stock plan, net

 

 

 

 

 

 

 

 

9

 

 

 

 

 

 

 

 

 

 

 

 

(9

)

 

 

 

 

 

 

 

 

(9

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,171

 

 

 

 

 

 

 

 

 

1,171

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(37

)

 

 

 

 

 

(37

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6,754

)

 

 

(6,754

)

Balance as of March 31, 2022

 

 

 

 

 

 

 

 

12,393

 

 

 

12

 

 

 

9,195

 

 

 

 

 

 

160,418

 

 

 

(37

)

 

 

(123,953

)

 

 

36,440

 

Issuance of common stock under stock plan, net

 

 

 

 

 

 

 

 

244

 

 

 

1

 

 

 

 

 

 

 

 

 

(51

)

 

 

 

 

 

 

 

 

(50

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,738

 

 

 

 

 

 

 

 

 

1,738

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4

)

 

 

 

 

 

(4

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,043

)

 

 

(7,043

)

Balance as of June 30, 2022

 

 

 

 

 

 

 

 

12,637

 

 

 

13

 

 

 

9,195

 

 

 

 

 

 

162,105

 

 

 

(41

)

 

 

(130,996

)

 

 

31,081

 

Exchange of exchangeable shares

 

 

 

 

 

 

 

 

83

 

 

 

 

 

 

(83

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under stock plan, net

 

 

 

 

 

 

 

 

37

 

 

 

 

 

 

 

 

 

 

 

 

(2

)

 

 

 

 

 

 

 

 

(2

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,448

 

 

 

 

 

 

 

 

 

1,448

 

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5

 

 

 

 

 

 

5

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,008

)

 

 

(4,008

)

Balance as of September 30, 2022

 

 

 

 

$

 

 

 

12,757

 

 

$

13

 

 

 

9,112

 

 

$

 

 

$

163,551

 

 

$

(36

)

 

$

(135,004

)

 

$

28,524

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Series A Special Voting

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Accumulated Other

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Common Stock

 

 

Exchangeable Shares

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Total

 

Balance as of December 31, 2020

 

 

 

 

$

 

 

 

5,241

 

 

$

5

 

 

 

 

 

$

 

 

$

102,361

 

 

$

 

 

$

(106,287

)

 

$

(3,921

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,177

 

 

 

 

 

 

 

 

 

1,177

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,157

)

 

 

(4,157

)

Balance as of March 31, 2021

 

 

 

 

 

 

 

 

5,241

 

 

 

5

 

 

 

 

 

 

 

 

 

103,538

 

 

 

 

 

 

(110,444

)

 

 

(6,901

)

Issuance of common stock under stock plan, net

 

 

 

 

 

 

 

 

16

 

 

 

 

 

 

 

 

 

 

 

 

30

 

 

 

 

 

 

 

 

 

30

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,137

 

 

 

 

 

 

 

 

 

1,137

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5,430

)

 

 

(5,430

)

Balance as of June 30, 2021

 

 

 

 

 

 

 

 

5,257

 

 

 

5

 

 

 

 

 

 

 

 

 

104,705

 

 

 

 

 

 

(115,874

)

 

 

(11,164

)

Issuance of common stock under stock plan, net

 

 

 

 

 

 

 

 

452

 

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

1

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,148

 

 

 

 

 

 

 

 

 

1,148

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,821

)

 

 

(3,821

)

Balance as of September 30, 2021

 

 

 

 

$

 

 

 

5,709

 

 

$

5

 

 

 

 

 

$

 

 

$

105,854

 

 

$

 

 

$

(119,695

)

 

$

(13,836

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


 

PERASO INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(17,805

)

 

$

(13,407

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

2,289

 

 

 

783

 

Stock-based compensation

 

 

4,357

 

 

 

3,461

 

Allowance for doubtful accounts

 

 

683

 

 

 

 

Change in fair value of warrant liability

 

 

 

 

 

(113

)

Amortization of debt discount

 

 

 

 

 

1,540

 

Accrued interest expense

 

 

4

 

 

 

661

 

Amortization of lease right-of-use assets

 

 

418

 

 

 

182

 

Change in operating lease liabilities

 

 

(462

)

 

 

(177

)

Other

 

 

199

 

 

 

26

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

117

 

 

 

(16

)

Inventories

 

 

(1,447

)

 

 

(756

)

Tax credits and receivables

 

 

23

 

 

 

(434

)

Prepaid expenses and other assets

 

 

190

 

 

 

212

 

Deferred cost of net revenue

 

 

(600

)

 

 

 

Accounts payable

 

 

(193

)

 

 

925

 

Deferred revenue and other liabilities

 

 

(1,192

)

 

 

56

 

Net cash used in operating activities

 

 

(13,419

)

 

 

(7,057

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(577

)

 

 

(57

)

Purchases of intangible assets

 

 

(21

)

 

 

(95

)

Proceeds from maturities of marketable securities

 

 

11,534

 

 

 

 

Purchases of marketable securities

 

 

(497

)

 

 

 

Net cash provided by (used in) investing activities

 

 

10,439

 

 

 

(152

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Taxes paid to net share settle equity awards

 

 

(61

)

 

 

 

Repayment of loans

 

 

 

 

 

(184

)

Proceeds from exercise of stock options

 

 

 

 

 

31

 

Net proceeds from loan facility

 

 

 

 

 

1,262

 

Net proceeds from convertible debenture

 

 

 

 

 

5,545

 

Net cash provided by (used in) financing activities

 

 

(61

)

 

 

6,654

 

Net decrease in cash and cash equivalents

 

 

(3,041

)

 

 

(555

)

Cash and cash equivalents at beginning of period

 

 

5,893

 

 

 

1,712

 

Cash and cash equivalents at end of period

 

$

2,852

 

 

$

1,157

 

Supplemental disclosure:

 

 

 

 

 

 

 

 

Recognition of right-of-use assets and lease liabilities

 

$

1,003

 

 

$

 

Unrealized loss on available-for-sale securities

 

$

36

 

 

$

 

Settlement of loan facility against tax receivables

 

$

 

 

$

1,093

 

Fair value of new warrants issued recognized as debt discount

 

$

 

 

$

2,604

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6


 

 

PERASO INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. The Company and Summary of Significant Accounting Policies

Peraso Inc., formerly known as MoSys, Inc. (the Company), was incorporated in California in 1991 and reincorporated in 2000 in Delaware. The Company is a fabless semiconductor company specializing in the development of millimeter wave (mmWave), which is generally described as the frequency band from 24 Gigahertz (GHz) to 300GHz, wireless technology. The Company derives revenue from selling its 60GHz and 5G semiconductor devices and modules and performance of non-recurring engineering services. The Company also manufactures and sells high-performance memory semiconductor devices for a wide range of markets and receives royalties from licensees of its memory technology.

On September 14, 2021, the Company and its subsidiaries, 2864552 Ontario Inc. (Callco) and 2864555 Ontario Inc. (Canco), entered into an Arrangement Agreement (the Arrangement Agreement) with Peraso Technologies Inc. (Peraso Tech), a corporation existing under the laws of the province of Ontario, to acquire all of the issued and outstanding common shares of Peraso Tech (the Peraso Shares), including those Peraso Shares to be issued in connection with the conversion or exchange of secured convertible debentures and common share purchase warrants of Peraso Tech, as applicable, by way of a statutory plan of arrangement (the Arrangement) under the Business Corporations Act (Ontario). On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, the Arrangement was completed and, the Company changed its name to “Peraso Inc.” and began trading on the Nasdaq Stock Market (the Nasdaq) under the symbol “PRSO.”

For accounting purposes, Peraso Tech, the legal subsidiary, has been treated as the accounting acquirer and the Company, the legal parent, has been treated as the accounting acquiree. The transaction was accounted for as a reverse acquisition in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) No. 805, Business Combinations (ASC 805). Accordingly, these condensed consolidated financial statements are a continuation of Peraso Tech’s consolidated financial statements prior to December 17, 2021 and exclude the statements of operations and comprehensive loss, statement of stockholders’ equity and statements of cash flows of the Company prior to December 17, 2021. See Note 2 for additional disclosure.

The accompanying condensed consolidated financial statements of the Company have been prepared without audit.  

The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any other future period.

Liquidity

The Company incurred net losses of approximately $17.8 million for the nine months ended September 30, 2022 and $10.9 million for the year ended December 31, 2021 and had an accumulated deficit of approximately $135.0 million as of September 30, 2022.  These and prior year losses have resulted in significant negative cash flows and have required the Company to raise substantial amounts of additional capital. To date, the Company has primarily financed its operations through multiple offerings of common stock and issuance of convertible notes and loans to investors and affiliates.

7


 

The Company expects to continue to incur operating losses for the foreseeable future as it secures additional customers and continues to invest in the commercialization of its products. The Company will need to increase revenues substantially beyond levels that it has attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.  As a result of the Company’s expected operating losses and cash burn for the foreseeable future, as well as recurring losses from operations, if the Company is unable to raise sufficient capital through additional debt or equity arrangements, there will be uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. These condensed consolidated financial statements do not include any adjustments that might result from this uncertainty. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to the Company. The Company’s primary focus is producing and selling its products.  If the Company is unsuccessful in these efforts, it will need to implement additional cost reduction strategies, which could further affect its near- and long-term business plan. These efforts may include, but are not limited to, reducing headcount and curtailing business activities.

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year. Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows. The Company previously classified intangible asset amortization expense related to the developed technology and customer relationships intangibles within research and development expenses (R&D) in its condensed consolidated statements of operations and comprehensive loss. Amortization expense on the developed technology intangible asset is now classified within cost of net revenue, and amortization expense on customer relationships is now classified in selling, general and administrative expenses (SG&A). Prior period amounts have been conformed to the current period presentation. See Note 5 for additional disclosure.

Risks and Uncertainties

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.

COVID-19

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020.  This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Material estimates may include assumptions made in determining reserves for uncollectible receivables, inventory write-downs, impairment of long-term assets, purchase price allocations, valuation allowance on deferred tax assets, accruals for potential liabilities and assumptions made in valuing equity instruments. Actual results could differ from those estimates.

Cash Equivalents and Investments

The Company has invested its excess cash in money market accounts, certificates of deposit, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term and long-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income (loss). Realized gains and losses and declines in the value judged to be other-than-temporary are included in the other income, net line item in the condensed consolidated statements of operations. The cost of securities sold is based on the specific identification method.

8


 

Fair Value Measurements

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1—Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date.

Level 2—Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities include cash equivalents and available-for-sale securities, which consisted primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities.

Level 3—Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of lease obligations and long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

Allowance for Doubtful Accounts

The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. The allowance for doubtful accounts receivable was approximately $683,000 as of September 30, 2022 and approximately $61,000 as of December 31, 2021.

Inventories

The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. Costs of inventories primarily consisted of material and third party assembly costs. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and quantification of slow moving inventory items. The Company recorded write-downs of inventory of approximately $420,000 and $56,000 during the nine months ended September 30, 2022 and 2021, respectively.

Tax Credits and Receivables

The Company is registered for the Canadian federal and provincial goods and services taxes. As such, the Company is obligated to collect from third parties and is entitled to claim sales taxes paid on its expenses and capital expenditures incurred in Canada.

The Company participated in the Canadian government’s Scientific Research and Experimental Development (SRED) Program, which uses tax incentives to encourage Canadian businesses to conduct research and development (R&D) in Canada. As a part of the program, the Company may be entitled to a receivable in the form of tax credits or incentives. The Company records refundable tax credits as a reduction of expense and receivable when the Company can reasonably estimate the amounts and it is more likely than not, the credit will be received.

A government refund or subsidy that is compensation for expenses or losses already incurred, or for which there are no future related costs, is recognized in the statement of operations in the period in which it becomes receivable.

9


 

As of December 17, 2021, Peraso Tech ceased to be a Canadian Controlled Private Corporation, as defined by the government of Canada, and the Company is no longer eligible for the expenditure refund program. However, it is eligible for a tax credit of 15% on qualified SRED expenditures.  Unused SRED tax credits can be carried back three years or forward for 20 years.

Intangible and Long-lived Assets

Intangible assets are recorded at cost and amortized on a straight-line method over their estimated useful lives of three to ten years. Amortization of developed technology and other intangibles directly related to the Company’s products is included in cost of net revenue, while amortization of customer relationships and other intangibles not associated with the Company’s products is included in SG&A in the condensed consolidated statements of operations.

The Company regularly reviews the carrying value and estimated lives of its long-lived assets and finite-lived intangible assets to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the long-lived asset group over the asset’s fair value.

Purchased Intangible Assets

Intangible assets acquired in business combinations are accounted for based on the fair value of assets purchased and are amortized over the period in which economic benefit is estimated to be received. Intangible assets subject to amortization, including those acquired in business combinations were as follows (amounts in thousands):

 

 

 

September 30, 2022

 

 

 

Gross

 

 

 

 

 

 

Net

 

 

 

Carrying

 

 

Accumulated

 

 

Carrying

 

 

 

Amount

 

 

Amortization

 

 

Amount

 

Developed technology

 

$

5,726

 

 

$

1,133

 

 

$

4,593

 

Customer relationships

 

 

2,556

 

 

 

506

 

 

 

2,050

 

Other

 

 

186

 

 

 

26

 

 

 

160

 

Total

 

$

8,468

 

 

$

1,665

 

 

$

6,803

 

 

 

 

December 31, 2021

 

 

 

Gross

 

 

 

 

 

 

Net

 

 

 

Carrying

 

 

Accumulated

 

 

Carrying

 

 

 

Amount

 

 

Amortization

 

 

Amount

 

Developed technology

 

$

5,726

 

 

$

60

 

 

$

5,666

 

Customer relationships

 

 

2,556

 

 

 

27

 

 

 

2,529

 

Other

 

 

165

 

 

 

5

 

 

 

160

 

Total

 

$

8,447

 

 

$

92

 

 

$

8,355

 

Developed technology primarily consisted of MoSys’ products that have reached technological feasibility and primarily relate to its memory semiconductor products and technology. The value of the developed technology was determined by discounting estimated net future cash flows of these products. The Company is amortizing the developed technology on a straight-line basis over four years. Amortization related to developed technology of $0.4 million and $1.1 million for the three and nine months ended September 30, 2022, respectively, has been included in cost of net revenue in the condensed consolidated statements of operations and comprehensive loss.

Customer relationships relate to the Company's ability to sell existing and future versions of products to MoSys’ customers existing at the time of the arrangement. The fair value of the customer relationships was determined by discounting estimated net future cash flows from the customer relationships. The Company is amortizing customer relationships on a straight-line basis over an estimated life of 4 years. Amortization related to customer relationships of $0.2 million and $0.5 million for the three and nine months ended September 30, 2022, respectively, has been included in selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss.

Amortization expense was $0.5 million and $1.6 million for the three and nine months ended September 30, 2022, respectively. There was no material amortization expense for the three and nine months ended September 30, 2021.

10


 

As of September 30, 2022, estimated future amortization expense related to intangible assets was as follows (in thousands):

 

 

 

 

 

Year ending December 31,

 

 

 

 

2022

 

$

526

 

2023

 

 

2,099

 

2024

 

 

2,099

 

2025

 

 

2,011

 

2026

 

 

28

 

2027

 

 

10

 

Thereafter

 

 

30

 

 

 

$

6,803

 

 

 

 

 

 

 

Goodwill

The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. As the Company uses the market approach to determine the step one fair value of the reporting unit, the price of its common stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price and volume fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. If the fair value of the reporting unit exceeds the carrying value of net assets of the reporting unit, goodwill is not impaired. If the carrying value of the reporting unit’s goodwill exceeds its fair value, then the Company must record an impairment charge equal to the difference.

To date, as of September 30, 2022, the Company has not identified any goodwill impairment. However, current macroeconomic conditions, which have been impacted by the COVID-19 pandemic and inflation, could negatively impact our business and stock price and trigger the Company to test for impairment. The Company will continue to evaluate for impairment indicators, as necessary, on a quarterly basis.

.  

Leases

ASC No. 842, Leases (ASC 842) requires an entity to recognize a right-of-use asset and a lease liability for all leases with terms longer than 12 months. The Company adopted ASC 842 utilizing the modified retrospective transition method. The Company elected the practical expedient afforded in ASC 842 in which the Company did not reassess whether any contracts that existed prior to adoption have or contain leases or the classification of its existing leases.

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers and its amendments (ASC 606). As described below, the analysis of contracts under ASC 606 supports the recognition of revenue at a point in time, resulting in revenue recognition timing that is materially consistent with the Company’s historical practice of recognizing product revenue when title and risk of loss pass to the customer.

The Company generates revenue primarily from sales of integrated circuits and module products, performance of engineering services and licensing of its intellectual property. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

11


 

Product revenue

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company's contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less.

The Company may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.

Royalty and other

The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology.  Payments are received in the subsequent quarter. The Company also generates revenue from licensing its technology. The Company recognizes license fees as revenue at the point of time when the control of the license has been transferred and the Company has no continuing performance obligations to the customer.

Engineering services revenue

Engineering and development contracts with customers generally contain a single performance obligation that is delivered over time. Revenue is recognized using an output method that is consistent with the satisfaction of the performance obligation as a measure of progress.

Deferred Cost of Net Revenue

During the three months ended September 30, 2022, the Company had $1.1 million of product shipments for which the revenue recognition criteria under ASC 606 had not been met.  Accordingly, the Company has deferred the cost of net revenue associated with these shipments, and the amount deferred has been presented as deferred cost of net revenue in the condensed consolidated balance sheets.

Contract liabilities – deferred revenue

The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue. As of September 30, 2022 and December 31, 2021, contract liabilities were in a current position and included in deferred revenue.

During the nine months ended September 30, 2022, the Company recognized approximately $156,000 of revenue that had been included in deferred revenue as of December 31, 2021.

See Note 7 for disaggregation of revenue by geography.

The Company does not have significant financing components, as payments from customers are typically due within 60 days of invoicing, and the Company has elected the practical expedient to not value financing components that are less than one year. Shipping and handling costs are generally incurred by the customer, and, therefore, are not recorded as revenue.

Cost of Net Revenue

Cost of net revenue consists primarily of direct and indirect costs of product sales, including amortization of intangible assets and depreciation of production-related fixed assets.

Government Subsidies

A grant or subsidy that is compensation for expenses or losses already incurred, or for which there are no future related costs, is recognized in the statement of operations in the period in which it becomes receivable.

Starting in 2020, certain Canadian businesses, which experienced a drop in revenue during the COVID-19 pandemic, became eligible for rent and wage subsidies from the Canadian government. The Company’s subsidiary, Peraso Tech, began receiving subsidies on a monthly basis beginning in the fourth quarter of 2020 and ending in the fourth quarter of 2021.

12


 

During the nine months ended September 30, 2021, the Company recognized payroll subsidies of $1,102,616 as a reduction in the associated wage costs and rent subsidies of $195,995 as a reduction of operating expenses in the condensed consolidated statement of operations.

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees. The Company accounts for such grants based on ASC No. 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on a straight-line basis over the vesting period. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing (Black Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods.

Foreign Currency Transactions

The functional currency of the Company is the U.S dollar. All foreign currency transactions are initially measured and recorded in an entity’s functional currency using the exchange rate on the date of the transaction. All monetary assets and liabilities are remeasured at the end of each reporting period using the exchange rate at that date. All non-monetary assets and related expense, depreciation or amortization are not subsequently remeasured and are measured using the historical exchange rate. An average exchange rate may be used to recognize income and expense items earned or incurred evenly over a period. Foreign exchange gains and losses resulting from the settlement of such transactions are recognized in the statement of operations, except for the gains and losses arising from the conversion of the carrying amount of the foreign currency denominated convertible preferred shares into the functional currency that are presented as adjustment to the net loss to arrive at net loss attributable to common stockholders.

Per-Share Amounts

Basic net loss per share is computed by dividing net loss for the period by the weighted-average number of exchangeable shares and shares of common stock outstanding during the period. Diluted net loss per share gives effect to all potentially dilutive exchangeable and common shares outstanding during the period. Potentially dilutive common shares consist of incremental exchangeable shares and shares of common stock issuable upon the achievement of escrow terms, exercise of stock options, vesting of stock awards and exercise of warrants.  

The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands):  

 

 

 

 

 

 

September 30,

 

 

 

2022

 

 

2021

 

Escrow shares - exchangeable shares

 

 

1,313

 

 

 

 

Escrow shares - common stock

 

 

502

 

 

 

 

Options to purchase common stock

 

 

1,514

 

 

 

1,034

 

Unvested restricted common stock units

 

 

1,229

 

 

 

 

Convertible debt

 

 

 

 

 

5,500

 

Common stock warrants

 

 

134

 

 

 

508

 

Total

 

 

4,692

 

 

 

7,042

 

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments—Credit Losses. This ASU added a new impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The Company does not expect that the adoption of ASU No. 2016-13 will have a significant impact on the Company's consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (ASU 2021-04). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or

13


 

conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Note 2: Business Combination

Arrangement

As discussed in Note 1, on September 14, 2021, the Company and its newly formed subsidiaries, Callco and Canco, entered into the Arrangement Agreement with Peraso Tech. Prior to the Arrangement, as a fabless semiconductor company, the Company’s primary focus was the manufacture and sale of high-performance memory semiconductor devices for a wide range of markets. Peraso Tech was also a fabless semiconductor company specializing in the development of mmWave technology, including 60GHz and 5G products, and deriving revenue from selling semiconductor devices, proprietary modules based on its semiconductor devices and performance of non-recurring engineering services. The primary reason for the business combination was to produce a larger fabless semiconductor company with greater size and scale with access to the public capital markets for the benefit of the stockholders of both companies.

On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, including approvals from the stockholders of the Company and Peraso Tech, the Arrangement was completed.

Securities Conversion

Pursuant to the completion of the Arrangement, each Peraso Share that was issued and outstanding immediately prior to December 17, 2021 was converted into the right to receive 0.045239122387267 (the Exchange Ratio) newly issued shares of common stock of the Company or shares of Canco, which are exchangeable for shares of the Company’s common stock (Exchangeable Shares), at the election of each former Peraso Tech stockholder. In addition, all of Peraso Tech’s outstanding stock options and other securities exercisable or exchangeable for, or convertible into, and any other rights to acquire Peraso Shares were exchanged for securities exercisable or exchangeable for, or convertible into, or other rights to acquire the Company’s common stock. Immediately following the completion of the Arrangement, the former security holders of Peraso Tech owned approximately 61%, on a fully-diluted basis, of the Company’s common stock, and the former shareholders of Peraso Tech, as a group, obtained control of the Company. While the Company was the legal acquirer of Peraso Tech, Peraso Tech was deemed to be the acquirer for accounting purposes.

In addition, pursuant to the terms of the Arrangement Agreement, (i) certain warrants to purchase Peraso Shares outstanding immediately prior to the closing of the Arrangement were exercised in consideration for the issuance of Peraso Shares; (ii) each convertible debenture of Peraso Tech outstanding immediately prior to the closing of the Arrangement and all principal and accrued but unpaid interest thereon was converted into Peraso Shares at a conversion price equal to the conversion price set out in each such debenture; and (iii) each outstanding option to purchase Peraso Shares (each, a Peraso Option) was exchanged for a replacement option to purchase such number of shares of common stock that was equal to the product of (a) the number of Peraso Shares subject to the Peraso Options immediately before the closing of the Arrangement and (b) the Exchange Ratio, rounded down to the nearest whole number of shares of common stock.

Upon the closing of the Arrangement, an aggregate of 9,295,097 Exchangeable Shares and 3,558,151 shares of common stock were issued to the holders of Peraso Shares. Of such shares, pursuant to the terms of the Agreement, the Company held in escrow an aggregate of 1,312,878 Exchangeable Shares and 502,567 shares of common stock (collectively, the Escrow Shares). The Escrow Shares are escrowed pursuant to the terms of an escrow agreement on a pro rata basis from the aggregate consideration received by the holders of Peraso Shares, subject to the offset by the Company for any losses in accordance with the Agreement. Such Escrow Shares shall be released, subject to any offset claim, upon the satisfaction of the earlier of: (a) any date following the first anniversary of December 17, 2021 and prior to December 17, 2024 where the volume weighted average price of the common stock for any 20 trading days within a period of 30 consecutive trading days is at least $8.57 per share, subject to adjustment for stock splits or other similar transactions; (b) the date of any sale of all or substantially all of the assets or shares of the Company; or (c) the date of any bankruptcy,

14


 

insolvency, restructuring, receivership, administration, wind-up, liquidation, dissolution, or similar event involving the Company. All and any voting rights and other stockholder rights, other than with respect to dividends and distributions, with respect to the Escrow Shares are suspended until the Escrow Shares are released from escrow.

The Exchangeable Share structure is commonly used for cross-border transactions of this nature so as to provide non-tax-exempt Canadian shareholders with the same economic rights and benefits as holders of the Company’s shares into which the Exchangeable Shares are exchangeable, while allowing those Canadian shareholders to benefit from the tax-rollover available on the issuance of the Exchangeable Shares. In general terms, by choosing to acquire Exchangeable Shares from Canco, such a former Peraso Tech shareholder was able to rely on a rollover rule in the Income Tax Act (Canada) in order to defer any capital gain that he/she/it would have otherwise realized.

Callco was incorporated to exercise the call rights, while Canco was incorporated to acquire the shares of Peraso Tech from Canadian shareholders that wished to receive Exchangeable Shares as consideration, so it was a tax deferred transaction for such Canadian shareholders. The use of a separate entity, Callco, helps maximize cross border paid-up capital, which represents the amount that can generally be distributed free of Canadian withholding tax. The call rights also allow Callco to “purchase” the Exchangeable Shares rather than having them redeemed by Canco on a redemption or retraction or in connection with a liquidity event, thus avoiding the adverse deemed dividend tax consequences to shareholders that may arise from a redemption or retraction of Exchangeable Shares.

Holders of Exchangeable Shares have the right at any time (the Retraction Right) to retract or redeem any or all of the Exchangeable Shares owned by them for an amount per share equal to the market price of a share of the Company’s common stock plus the full amount of all declared and unpaid dividends on such Exchangeable Share (the Exchangeable Share Purchase Price). The Exchangeable Share Purchase Price is payable only by the Company delivering or causing to be delivered to the relevant holder one share of the Company’s common stock for each Exchangeable Share purchased plus a cash amount equal to the amount of any accrued and unpaid dividends on such Exchangeable Share. The Company and Callco each have an overriding right, in the event that a holder of Exchangeable Shares exercises its Retraction Right, to redeem from such holder all, but not less than all, of the Exchangeable Shares tendered for redemption.

The Exchangeable Shares are subject to redemption by the Company, Callco and Canco at the Exchangeable Share Purchase Price, on the “Redemption Date,” which date shall be no earlier than the seventh anniversary of the date on which Exchangeable Shares are first issued, unless: (a) less than 10% of the aggregate number of Exchangeable Shares issued remain outstanding; (b) there is a change in control of the Company (defined generally as (i) any merger, amalgamation, arrangement, takeover bid or tender offer, material sale of shares or rights or interests that results in the holders of outstanding voting securities of the Company directly or indirectly owning, or exercising control or direction over, voting securities representing less than 50% of the total voting power of all of the voting securities of the surviving entity; or (ii) any sale or disposition of all or substantially of the Company’s assets), and (c) upon the occurrence of certain other events. The Exchangeable Share Purchase Price is payable only by the Company delivering or causing to be delivered to the relevant holder one share of the Company’s common stock for each Exchangeable Share purchased plus a cash amount equal to the amount of any accrued and unpaid dividends on such Exchangeable Share.

In the event of the liquidation, dissolution or winding-up of Canco, holders of Exchangeable Shares have the right to receive in respect of each Exchangeable Share held by such holder, an amount per share equal to the Exchangeable Share Purchase Price, which shall be satisfied in full by Canco by delivering to such holder one Company Share, plus an amount equal to the Dividend Amount. The Company and Callco each have an overriding right to purchase from all holders all but not less than all of the Exchangeable Shares upon the occurrence of such events.

In addition, the Company and Callco have the right to purchase all outstanding Exchangeable Shares at the Exchangeable Share Purchase Price if there is a change of law that permits holders of Exchangeable Shares to exchange their Exchangeable Shares for shares of common stock on a basis that will not require holders to recognize any gain or loss or any actual or deemed dividend for Canadian tax purposes.

The holders of Exchangeable Shares have an “automatic exchange right” in the event of any insolvency, liquidation, dissolution or winding-up or in general, related proceedings, of the Company for an amount per share equal to the Exchangeable Share Purchase Price.

It is expected that Callco will exercise its call rights, as that is more beneficial to the holders of the Exchangeable Shares. Once Callco acquires the Exchangeable Shares from a holder, it (Callco and the Company) is obligated to deliver the Company shares to the holder. Callco discharges this obligation by arranging for the Company to issue and deliver those shares to the holders on behalf of Callco. As consideration for satisfying the delivery obligation, Callco would issue its own shares to the Company.

15


 

There are no cash redemption features, as all redemption and exchange scenarios are payable in a share of the Company’s common stock. Neither Canco, Callco, or the Company assume any tax liabilities of a former Peraso Tech shareholder who acquired Exchangeable Shares under the plan of arrangement. The purchase price computed upon the exercise of rights pertaining to retraction, redemption, or liquidation, or otherwise giving rise to a purchase or cancellation of an Exchangeable Share, will, in all cases, consist of a 1:1 exchange involving the Company’s common stock, regardless of the market price of a share of the Company’s common stock.

In connection with the Arrangement, on December 15, 2021, the Company filed the Certificate of Designation of Series A Special Voting Preferred Stock (the Certificate) with the Secretary of State of the State of Delaware to designate Series A Special Voting Preferred Stock (the Special Voting Share) in accordance with the terms of the Arrangement Agreement in order to enable the holders of Exchangeable Shares to exercise their voting rights. The Special Voting Share was issued to a third-party administrative agent (the Agent) solely to facilitate the exercise of rights by holders of Exchangeable Shares. The rights of the Agent, as holder of the Special Voting Share, are limited to effecting the rights of the holders of the Exchangeable Shares; the Special Voting Share does not confer any independent rights to the Agent. Under the Certificate, when all of the Exchangeable shares have been converted into shares of the Company’s common stock, the Special Voting Share shall be automatically cancelled and shall not be reissued. Each Exchangeable Share is exchangeable for one share of common stock of the Company and while outstanding, the Special Voting Share enables holders of Exchangeable Shares to cast votes on matters for which holders of the common stock are entitled to vote, and by virtue of the share terms relating to the Exchangeable Shares, enable the Exchangeable Shares to receive dividends that are economically equivalent to any dividends declared with respect to the shares of common stock. As the Special Voting Share does not participate in dividends (only the Exchangeable Shares participate in dividends) and is not entitled to participate in the residual interest of the Company, it is not classified as an equity instrument in the Company’s financial statements.

The Exchangeable Shares, which can be converted into common stock at the option of the holder and have the same voting and dividend rights as common stock, are similar in substance to shares of common stock. Further, Canco and Callco are non-substantive entities, which are looked through with the Exchangeable Shares being, in substance, common stock of the Company. Therefore, the Exchangeable Shares have been included in the determination of outstanding common stock. The Special Voting Share was issued to a third-party administrative agent (the Agent) solely to facilitate the exercise of rights by holders of Exchangeable Shares, The rights of the Agent, as holder of the Special Voting Share, are limited to effecting the rights of the holders of the Exchangeable Shares; the Special Voting Share does not confer any independent rights to the Agent. Under the Certificate, when all of the Exchangeable shares have been converted into shares of the Company’s common stock, the Special Voting Share shall be automatically cancelled and shall not be reissued.

Reverse Acquisition Determination

Pursuant to ASC 805, the transaction was accounted for as a reverse acquisition because: (i) the stockholders of Peraso Tech owned the majority of the outstanding common stock of the Company after the share exchange; (ii) Peraso Tech appointed a majority of the Company’s board of directors; and (iii) Peraso Tech determined the officers of the Company.

16


 

Measuring the Consideration Transferred

In the reverse acquisition, the accounting acquirer did not issue any consideration to the accounting acquiree, rather the accounting acquiree issued its equity shares to the owners of the accounting acquirer in exchange for the accounting acquirer’s shares. The acquisition date fair value of the consideration transferred by the accounting acquirer for its interest in the accounting acquiree was calculated by Peraso Tech, as the fair value of the consideration effectively transferred. In accordance with ASC 805, the consideration effectively transferred between the Company (a public company as the accounting acquiree) and Peraso Tech (a private company as the accounting acquirer), was calculated as the fair value of the Company’s equity including the fair value of its common shares outstanding and its warrants, plus the portion of the share-based award fair value allocated to the pre-combination service of the accounting acquiree’s awards. The fair value of the total consideration effectively transferred is summarized in the following table (in thousands, except per-share amount):

 

 

 

 

 

 

Company share price (i)

 

$

4.21

 

Company common shares outstanding (ii)

 

 

8,716

 

 

 

 

 

 

Fair value of the Company's common shares outstanding

 

 

36,694

 

 

 

 

 

 

Fair value of the Company's warrants (iii)

 

 

301

 

 

 

 

 

 

Total fair value of the Company's share-based awards (iii)

 

 

782

 

Percent related to pre-combination service

 

 

80.76

%

Fair value of the Company's pre-combination service share-based awards (iii)

 

 

632

 

 

 

 

 

 

Consideration effectively transferred

 

$

37,627

 

 

 

 

 

 

 

 

 

 

 

(i) Represents the Company's share price as of December 16, 2021

 

(ii) Represents the Company's outstanding shares as of December 16, 2021

 

(iii) Represents the fair value of the Company's warrants outstanding and calculated as of December 16, 2021

 

 

 

 

 

 

 

 The following table summarizes the final allocation of the purchase price to the net assets acquired based on the respective fair value of the acquired assets and assumed liabilities of the accounting acquiree, which is the Company.

 

 

 

 

 

 

 

December 31,

 

 

 

2021

 

Assets:

 

(in thousands)

 

Cash, cash equivalents and investments

 

$

19,064

 

Other current assets

 

 

2,558

 

Other assets

 

 

833

 

Intangibles

 

 

 

 

   Developed technology

 

 

5,726

 

   Customer relationships

 

 

2,556

 

 

 

 

8,282

 

Goodwill

 

 

9,946

 

Liabilities:

 

 

 

 

Current liabilities

 

 

3,056

 

 

 

$

37,627

 

 

 

 

 

 

17


 

 

Unaudited pro forma results of operations for the three and nine months ended September 30, 2021 are included below as if the business combination occurred on January 1, 2021.  This summary of the unaudited pro forma results of operations is not necessarily indicative of what the Company’s results of operations would have been had Peraso Tech been acquired at the beginning of 2021, nor does it purport to represent results of operations for any future periods.

 

 

Three Months Ended

 

 

Nine Months Ended

 

(in thousands)

 

September 30, 2021

 

 

September 30, 2021

 

Revenue

 

$

3,354

 

 

$

7,659

 

Net loss

 

$

(5,535

)

 

$

(17,695

)

 

 

 

 

 

 

 

 

 

 

Note 3: Fair Value of Financial Instruments

The estimated fair values of financial instruments outstanding were (in thousands):

 

 

 

September 30, 2022

 

 

 

 

 

 

 

Unrealized

 

 

Unrealized

 

 

Fair

 

 

 

Cost

 

 

Gains

 

 

Loss

 

 

Value

 

Cash and cash equivalents

 

$

2,852

 

 

$

 

 

$

 

 

$

2,852

 

Short-term investments

 

 

1,107

 

 

 

 

 

 

(36

)

 

 

1,071

 

 

 

$

3,959

 

 

$

 

 

$

(36

)

 

$

3,923

 

 

 

 

December 31, 2021

 

 

 

 

 

 

 

Unrealized

 

 

Unrealized

 

 

Fair

 

 

 

Cost

 

 

Gains

 

 

Losses

 

 

Value

 

Cash and cash equivalents

 

$

5,893

 

 

$

 

 

$

 

 

$

5,893

 

Short-term investments

 

 

9,276

 

 

 

 

 

 

(9

)

 

 

9,267

 

Long-term investments

 

 

2,935

 

 

 

 

 

 

(7

)

 

 

2,928

 

 

 

$

18,104

 

 

$

 

 

$

(16

)

 

$

18,088

 

 

 

The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):

 

 

 

September 30, 2022

 

 

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$

72

 

 

$

72

 

 

$

 

 

$

 

Corporate notes and commercial paper

 

$

1,071

 

 

$

 

 

$

1,071

 

 

$

 

 

 

$

1,143

 

 

$

72

 

 

$

1,071

 

 

$

 

 

 

 

December 31, 2021

 

 

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Money market funds

 

$

1,159

 

 

$

1,159

 

 

$

 

 

$

 

Corporate notes and commercial paper

 

$

12,195

 

 

$

 

 

$

12,195

 

 

$

 

 

There were no transfers in or out of Level 1 and Level 2 securities during the nine months ended September 30, 2022 or December 31, 2021.

 

18


 

 

Note 4. Balance Sheet Detail

 

Inventories

 

 

September 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

 

(in thousands)

 

Raw materials

 

$

1,416

 

 

$

879

 

Work-in-process

 

 

2,728

 

 

 

2,170

 

Finished goods

 

 

1,127

 

 

 

775

 

 

 

$

5,271

 

 

$

3,824

 

 

Note 5. Revision of Prior Period Financial Statements

Prior to April 1, 2022, the Company classified amortization expense related to the developed technology and customer relationships intangible assets within R&D in its condensed consolidated statements of operations and comprehensive loss. Amortization expense on the developed technology intangible asset is now classified within cost of net revenue, and amortization expense on customer relationships is now classified in SG&A. Prior period amounts have been conformed to the current period presentation. The reclassification had no impact on the Company's net loss or cash flows for the three months ended March 31, 2022 and nine months ended September 30, 2022.

The effects of the adjustments for the three months ended March 31, 2022 were as follows (in thousands):

 

 

 

As Reported

 

 

Adjustment

 

 

As Revised

 

Condensed Consolidated Statement of Operations:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of net revenue

 

$

1,590

 

 

$

358

 

 

$

1,948

 

Gross profit

 

 

1,813

 

 

 

(358

)

 

 

1,455

 

Research and development

 

 

6,003

 

 

 

(517

)

 

 

5,486

 

Selling, general and administrative

 

 

2,546

 

 

 

159

 

 

 

2,705

 

Total operating expenses

 

$

8,549

 

 

$

(358

)

 

$

8,191

 

 

Note 6. Commitments and Contingencies

Leases

The Company has five facility leases that it accounts for under ASC 842, and these include the operating leases for its corporate facility in San Jose, California, and facilities in Toronto, Markham and Waterloo, Ontario, Canada. The Waterloo and Toronto leases expire in September 2022 and December 2023, respectively. The current San Jose lease with a sublessor expires in July 2022, and the Company entered into a new, direct lease with the facility landlord, dated April 13, 2022, for an 18-month term, which commenced July 15, 2022. In addition, on May 26, 2022, the Company entered into a new lease for a facility in Markham, Ontario with a 60-month term, which commenced June 21, 2022. The Markham landlord also provided a lease incentive of approximately $220,000 (the Incentive), which will be payable to the Company as follows: one-half of the Incentive payable subsequent to the completion of the improvements to the leased space and the second half-ratably on an annual basis commencing with the second year of the lease.

The right-to-use assets and corresponding liabilities for the facility leases were measured at the present value of the future minimum lease payments. The discount rate used to measure the lease assets and liabilities were 8%. Lease expense is recognized on a straight-line basis over the lease term.

19


 

On March 1, 2022, the Company entered into a 36-month finance lease agreement for the lease of equipment resulting in the recognition of a right-of-use asset and lease liability on the balance sheet of approximately $274,000.

The following table provides the details of right-of-use assets and lease liabilities as of September 30, 2022 (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

 

 

 

September 30, 2022

 

Right-of-use assets:

 

 

 

 

 

 

 

Operating leases

 

 

 

 

$

957

 

Finance lease

 

 

 

 

 

224

 

   Total right-of-use assets

 

 

 

 

$

1,181

 

Lease liabilities:

 

 

 

 

 

 

 

Operating leases

 

 

 

 

$

954

 

Finance lease

 

 

 

 

 

233

 

   Total lease liabilities

 

 

 

 

$

1,187

 

 

Future minimum payments under the leases at September 30, 2022 are listed in the table below (in thousands):

 

 

 

 

 

 

 

 

 

Year ending December 31,

 

 

 

 

 

 

 

2022

 

 

 

 

$

67

 

2023

 

 

 

 

 

742

 

2024

 

 

 

 

 

216

 

2025

 

 

 

 

 

132

 

2026

 

 

 

 

 

106

 

2027

 

 

 

 

 

67

 

Total future lease payments

 

 

 

 

 

1,330

 

Less: imputed interest

 

 

 

 

 

(143

)

Present value of lease liabilities

 

 

 

 

$

1,187

 

The following table provides the details of supplemental cash flow information (in thousands):

 

 

 

 

Nine Months Ended

 

 

 

 

September 30,

 

 

 

 

2022

 

 

2021

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

 

 

   Operating cash flows for leases

 

$

504

 

 

$

273

 

 

Rent expense was approximately $0.2 million for each of the three-month periods ended September 30, 2022 and 2021.  Rent expense was approximately $0.5 million for the nine months ended September 30, 2022 and $0.3 million for the nine months ended September 30, 2021. In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs related to the leased facilities and equipment.

20


 

Indemnification

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the nine months ended September 30, 2022 and 2021 related to these indemnifications.

The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements. 

Product Warranties

The Company warrants certain of its products to be free of defects generally for a period of three years. The Company estimates its warranty costs based on historical warranty claim experience and includes such costs in cost of net revenues. Warranty costs were not material for the nine months ended September 30, 2022 and 2021.

Legal Matters

The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Note 7. Business Segments, Concentration of Credit Risk and Significant Customers

The Company determined its reporting units in accordance with ASC 280, Segment Reporting (ASC 280). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.

Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments.

The Company recognized revenue from shipments of product, licensing of its technologies and performance of services to customers by geographical location as follows (in thousands):

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

North America

 

$

1,918

 

 

$

984

 

 

$

7,158

 

 

$

1,145

 

Hong Kong

 

 

447

 

 

 

1,027

 

 

 

1,328

 

 

 

2,057

 

Taiwan

 

 

131

 

 

 

(2

)

 

 

646

 

 

 

586

 

Japan

 

 

368

 

 

 

 

 

 

905

 

 

 

 

Rest of world

 

 

430

 

 

 

9

 

 

 

944

 

 

 

28

 

Total net revenue

 

$

3,294

 

 

$

2,018

 

 

$

10,981

 

 

$

3,816

 

 

21


 

 

Customers who accounted for at least 10% of total net revenue were:

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

 

2022

 

2021

 

2022

 

2021

Customer A

 

24%

 

*

 

24%

 

*

Customer B

 

22%

 

14%

 

28%

 

*

Customer C

 

14%

 

45%

 

12%

 

48%

Customer D

 

*

 

*

 

*

 

15%

Customer E

 

*

 

33%

 

*

 

18%

 

*

Represents less than 10%

 

As of September 30, 2022, two customers accounted for 60% of accounts receivable, and the Company recorded a provision for doubtful accounts of $683,000 against one of the customer’s receivables. Three customers accounted for 96% of accounts receivable as of December 31, 2021.

Note 8. Income Tax Provision

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized.

The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations.  All tax returns from 2015 to 2020 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years 2011 to 2020.  As of September 30, 2022, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.  

Note 9. Stock-Based Compensation

Common Stock Equity Plans

In 2010, the Company adopted the 2010 Equity Incentive Plan and later amended it in 2014, 2017 and 2018 (the Amended 2010 Plan). The Amended 2010 Plan was terminated in August 2019 and remains in effect as to outstanding equity awards granted prior to the date of expiration. No new awards may be made under the Amended 2010 Plan.

In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and it replaced the Amended 2010 Plan.  The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares were initially reserved for issuance.

In November 2021, in connection with the approval of the Arrangement, the Company’s stockholders approved an amendment increasing the number of shares reserved for issuance under the 2019 Plan by 3,106,937 shares.

Under the 2019 Plan, the term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant.  Generally, awards under the 2019 Plan will vest over a three to four-year period, and options will have a term of 10 years from the date of grant.  In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.

In connection with the Arrangement, the Company assumed the Peraso Technologies Inc. 2009 Share Option Plan (the 2009 Plan) and all outstanding options granted pursuant to the terms of the 2009 Plan. Each outstanding, unexercised and unexpired option under the 2009 Plan, whether vested or unvested, was assumed by the Company and converted into options to purchase shares of the Company’s common stock and became exercisable by the holder of such option in accordance with its terms, with (i) the number of shares of common stock subject to each option multiplied by the Exchange Ratio and (ii) the per share exercise price upon the exercise of each option divided by the Exchange Ratio. In connection with the Arrangement, no further awards will be made under the 2009 Plan.  

The 2009 Plan, the Amended 2010 Plan and the 2019 Plan are referred to collectively as the “Plans.”

22


 

Stock-Based Compensation Expense

The Company reflected compensation costs of $3.4 million and $3.5 million related to the vesting of stock options during the nine-month periods ended September 30, 2022 and 2021, respectively. At September 30, 2022, the unamortized compensation cost was approximately $8.9 million related to stock options and is expected to be recognized as expense over a weighted average period of approximately 2.3 years. The Company reflected compensation costs of $1.0 million and zero related to the vesting of restricted stock options during the nine months ended September 30, 2022 and 2021, respectively.   The unamortized compensation cost at September 30, 2022 was $2.3 million related to restricted stock units and is expected to be recognized as expense over a weighted average period of approximately 2.3 years.

 

Valuation Assumptions and Expense Information for Stock-Based Compensation

There were no stock options granted or exercised during the nine months ended September 30, 2022. There were no stock options granted and stock options were exercised for 452 shares of common stock during the nine months ended September 30, 2021. 

Common Stock Options and Restricted Stock

The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant.  Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant.  In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control (as defined in the 2019 Plan) of the Company.  

The following table summarizes the activity in the shares available for grant under the Plans during the nine months ended September 30, 2022 (in thousands, except exercise price):

 

 

 

 

 

 

Options Outstanding

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

Shares

 

 

 

 

 

Average

 

 

 

Available

 

Number of

 

 

Exercise

 

 

 

for Grant

 

Shares

 

 

Prices

 

Balance as of December 31, 2021

 

 

3,024

 

 

1,558

 

 

$

3.49

 

Options cancelled

 

 

 

 

(13

)

 

$

10.98

 

Balance as of March 31, 2022

 

 

3,024

 

 

1,545

 

 

$

3.43

 

RSUs granted

 

 

(1,511

)

 

 

 

$

-

 

RSUs cancelled and returned to the Plan

 

 

43

 

 

 

 

$

-

 

Options cancelled

 

 

 

 

(8

)

 

$

2.63

 

Balance as of June 30, 2022

 

 

1,556

 

 

1,537

 

 

$

3.43

 

RSUs granted

 

 

(67

)

 

 

 

$

-

 

RSUs cancelled and returned to the Plan

 

 

103

 

 

 

 

$

-

 

Options cancelled

 

 

 

 

(23

)

 

$

2.57

 

Balance as of September 30, 2022

 

 

1,592

 

 

1,514

 

 

$

3.39

 

 

 

23


 

 

A summary of RSU activity under the Plans is presented below (in thousands, except for fair value):

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Average

 

 

 

Number of

 

 

Grant-Date

 

 

 

Shares

 

 

Fair Value

 

Non-vested shares as of December 31, 2021

 

 

88

 

 

$

4.84

 

Vested

 

 

(13

)

 

$

3.70

 

Non-vested shares as of March 31, 2022

 

 

75

 

 

$

5.67

 

Granted

 

 

1,511

 

 

 

 

Vested

 

 

(271

)

 

$

2.49

 

Cancelled

 

 

(12

)

 

 

 

Non-vested shares as of June 30, 2022

 

 

1,303

 

 

$

2.28

 

Granted

 

 

67

 

 

 

 

Vested

 

 

(38

)

 

$

2.45

 

Cancelled

 

 

(103

)

 

 

 

Non-vested shares as of September 30, 2022

 

 

1,229

 

 

$

2.27

 

 

 

 

 

 

 

 

 

 

 

The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2022 (in thousands, except contractual life and exercise price):

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remaining

 

 

Weighted

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

Contractual

 

 

Average

 

 

 

 

 

 

Average

 

 

Aggregate

 

 

 

Number

 

 

Life

 

 

Exercise

 

 

Number

 

 

Exercise

 

 

Intrinsic

 

Range of Exercise Price

 

Outstanding

 

 

(in Years)

 

 

Price

 

 

Exercisable

 

 

Price

 

 

value

 

$1.57 - $14.99

 

 

1,502

 

 

 

7.89

 

 

$

2.65

 

 

 

865

 

 

$

2.52

 

 

$

10

 

$15.00 - $25.59

 

 

5

 

 

 

0.98

 

 

$

17.12

 

 

 

5

 

 

$

17.12

 

 

$

 

$25.60 - $143.99

 

 

1

 

 

 

3.89

 

 

$

101.27

 

 

 

1

 

 

$

101.27

 

 

$

 

$144.00 - $409.99

 

 

5

 

 

 

3.74

 

 

$

144.00

 

 

 

5

 

 

$

144.00

 

 

$

 

$410.00 - $924.00

 

 

1

 

 

 

1.95

 

 

$

410.00

 

 

 

1

 

 

$

410.00

 

 

$

 

$1.57 - $924.00

 

 

1,514

 

 

 

7.85

 

 

$

3.39

 

 

 

877

 

 

$

3.81

 

 

$

10

 

 

 

 

Note 10. Equity

 

Warrants

As of September 30, 2022, the Company had the following warrants outstanding (share amounts in thousands):

 

 

 

Type

 

Number of Shares

 

 

Exercise Price

 

 

Expiration

Common stock

 

 

33

 

 

$

47.00

 

 

January 2023

Common stock

 

 

101

 

 

$

2.40

 

 

October 2023

 

24


 

 

Note 11. Debt

 

Loan Facilities

On November 30, 2020, the Company entered into a loan agreement (the SRED Financing) to raise funds against the Company’s present and after acquired personal property. On February 5, 2021, March 5, 2021 and September 17, 2021 the Company raised additional funds from the second, third and fourth draws under the SRED financing of $274,715 (CDN$350,000), $274,715 (CDN$350,000) and $745,655 (CDN$950,000) respectively, totaling year to date gross proceeds of $1,295,085 (CDN$1,650,000) net of financing fees of $32,770 (CDN$41,750). Each borrowing carried an interest rate of 1.6% per month, compounded monthly (20.98%). The SRED financing was sanctioned against the Company’s SRED tax credit refund.

The first, second and third draws, including interest of $136,900 (CDN$174,417), were repaid through proceeds from the Company’s tax credit refund of $1,093,230 (CDN$1,392,831) received in August 2021, and the balance of $184,558 (CDN$ 235,132) was paid from the fourth draw.  The remaining loan balance, including interest, of $816,964 (CDN$1,044,177) was repaid on December 16, 2021.

Interest expense of $870,212 for the three months ended September 30, 2021 consisted of i) $625,913 of amortization of debt discount, ii) $212,971 of interest expense on convertible debt, which was outstanding and retired in 2021, and iii) $31,328 of interest expense on the SRED financing. Interest expense of $2,170,059 for the nine months ended September 30, 2021 consisted of i) $1,510,368 of amortization of debt discount, ii) $522,274 of interest expense on convertible debt, which was outstanding and retired in 2021, and iii) $137,417 of interest expense on the SRED financing. 

A family member of one of the Company’s executive officers serves as a consultant to the Company. During the nine months ended September 30, 2022 and 2021, the Company paid approximately $126,800 and $153,100, respectively, to the consultant. Additionally, a family member of one of the Company’s executive officers is an employee of the Company. During the nine months ended September 30, 2022, the Company paid approximately $127,500 to the employed family member, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718, of an RSU awarded in April 2022. During the nine months ended September 30, 2021, the Company paid approximately $69,000 to the employed family member.

Note 13. License and Asset Sale Transaction

 

On August 5, 2022, the Company entered into a Technology License and Patent Assignment Agreement (the Intel Agreement) with Intel Corporation (Intel), pursuant to which Intel: (i) licensed from the Company, on an exclusive basis, certain software and technology assets related to the Company’s Stellar packet classification intellectual property, including its graph memory engine technology, and any roadmap variant, in the form existing as of the date of the Agreement (the Licensed Technology); (ii) acquired from the Company certain patent applications and patents owned by the Company; and (iii) assumed a professional services agreement, dated March 24, 2020, between Fabulous Inventions AB (Fabulous) and the Company (the Fabulous Agreement), pursuant to which, among other things, the Company licensed from Fabulous certain technology incorporated into the Licensed Technology.

 

As consideration for the Company to enter into the Agreement, Intel agreed to pay the Company $3,062,500 at the closing of the transaction (the Closing) and $437,500 (the Holdback) upon the satisfaction by the Company, as mutually agreed upon by the parties in good faith, of certain release criteria set forth in the Agreement relating to various due diligence activities of Intel regarding the Licensed Technology (the Release Criteria). Intel and the Company agreed to work together in good faith so as to ensure that the Release Criteria is satisfied by the Company no later than six months following the Closing.

 

The Company determined that the license and asset sale did not qualify as a sale of a business, but as a sale of a non-financial asset, with the resultant gain recorded as income from operations in accordance with ASC 610-20, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets. During the three months ended September 30, 2022, the Company recognized a $2.6 million gain on this transaction, net of transaction costs, which was recorded as a reduction of operating expenses in the condensed consolidated statements of operations and comprehensive loss.  Any gain related to the Holdback will be recorded when the Release Criteria have been satisfied, which is expected to be within six months of August 5, 2022.

 

 

25


 

 

 

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this report. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising effort., the impacts of COVID-19 on our business, the effects of the Russia/Ukraine conflict, and inflation, which could cause customers to delay or reduce purchases of our products or delay payments to us, which would adversely affect our financial results, including cash flows, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our annual report on Form 10-K for the year ended December 31, 2021 and the risk factors described below under Item 1A of this Form 10-Q. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future.

Overview

We were formerly known as MoSys, Inc. (MoSys) and were incorporated in California in 1991 and reincorporated in Delaware in 2000. On September 14, 2021, we and our subsidiaries, 2864552 Ontario Inc. and 2864555 Ontario Inc., entered into an Arrangement Agreement (the Arrangement Agreement) with Peraso Technologies Inc. (Peraso Tech), a corporation existing under the laws of the province of Ontario, to acquire all of the issued and outstanding common shares of Peraso Tech (the Peraso Shares), including those Peraso Shares to be issued in connection with the conversion or exchange of secured convertible debentures and common share purchase warrants of Peraso Tech, as applicable, by way of a statutory plan of arrangement (the Arrangement) under the Business Corporations Act (Ontario). On December 17, 2021, following the satisfaction of the closing conditions set forth in the Arrangement Agreement, the Arrangement was completed and the Company changed its name to “Peraso Inc.” and began trading on the Nasdaq Stock Market under the symbol “PRSO.”

For accounting purposes, the legal subsidiary, Peraso Tech, has been treated as the accounting acquirer and we, the legal parent, have been treated as the accounting acquiree. The transaction has been accounted for as a reverse acquisition in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) No. 805, Business Combinations. Accordingly, the financial condition and results of operations discussed herein are a continuation of Peraso Tech’s financial results prior to December 17, 2021 and exclude the financial results of us prior to December 17, 2021. See Note 2 to the condensed consolidated financial statements for additional disclosure.

Our strategy and primary business objective is to be a profitable, IP-rich, fabless semiconductor company offering integrated circuits (ICs), modules and related non-recurring engineering services. We specialize in the development of mmWave semiconductors, primarily in the 60 GHz spectrum band for 802.11ad/ay compliant devices and in the 28/39 GHz spectrum bands for 5G-compliant devices. We derive our revenue from selling semiconductor devices, as well as modules based on using those mmWave semiconductor devices. We have pioneered a high-volume mmWave production test methodology using standard low cost production test equipment. It has taken us several years to refine performance of this production test methodology, and we believe this places us in a leadership position in addressing operational challenges of delivering mmWave products into high-volume markets. During 2021, we augmented our business model and began selling complete mmWave modules. The primary advantage provided by a module is the silicon and the antenna are integrated into a single device. A differentiating characteristic of mmWave technology is that the radio frequency amplifiers must be as close as possible to the antenna to minimize loss, and, by providing a module, we can guarantee the performance of the amplifier/antenna interface.

We also have a memory product line, marketed under the Accelerator Engine name, which includes our Bandwidth Engine IC products, which integrate our proprietary, 1T-SRAM high-density embedded memory and a highly-efficient, serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance.  As we are not developing new memory products, from a product development perspective, we continue to leverage our current technologies and core competencies to expand our product offerings without incurring significant additional research and development (R&D) expenses.

We incurred net losses of approximately $16.6 million for the nine months ended September 30, 2022 and $10.9 million for the year ended December 31, 2021, and we had an accumulated deficit of approximately $133.8 million as of September 30, 2022. These and prior year losses have resulted in significant negative cash flows and historically have required us to raise substantial amounts of additional capital. We expect to continue to incur operating losses and will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.

26


 

COVID-19 and Macroeconomic Factors

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by the U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.

Since March 2020, certain jurisdictions in which we operate have issued ’shelter-in-place” orders. We have complied with these orders and, when such orders were in place, minimized business activities at our facilities. We have implemented a teleworking policy for our employees and contractors to reduce on-site activity.

We believe that as the COVID-19 pandemic evolves, the direct and indirect impacts of the pandemic on global macroeconomic conditions, as well as conditions specific to us, are becoming more difficult to isolate or quantify. In addition, these direct and indirect factors can make it difficult to isolate and quantify the portion of our costs that are a direct result of the pandemic and costs arising from factors that may have been influenced by the pandemic, such as supply chain constraints, rising inflation, and recessionary fears. We expect these factors and their effects on our operations may persist for a longer period, even after the COVID-19 pandemic has subsided. We continue to closely monitor impacts, especially to customer programs and our supply chain. We are working internally and with suppliers on programs (i.e., new production flows, etc.) to allow us to increase our peak throughput to better handle unplanned disruptions to our supply chain. To date, we have not experienced a material impact on our cash flows, liquidity, capital resources, cash requirements, financial position, or results of operations, attributable to the global semiconductor supply chain disruption and inflation. We have experienced increased prices from our suppliers, and, for certain products, we have increased prices to our customers to mitigate the impacts, although to date in 2022 the impacts of these price increases have been minimal. We have and continue to experience longer lead times for certain components used to manufacture our products, and, therefore, and, in response, we have identified second and third sources for certain components used in our module products. Also, we have increased lead times for our customers. We have not experienced any issues over our product quality and product development activities, as we do not rely significantly on outside vendors to manage and perform these activities for us. We currently have not identified any current impacts of the supply chain disruption and inflation that will affect our future results, and it is difficult to differentiate whether higher prices are due to supply chain disruption, inflation or a mix of both.

While we believe that our operations personnel are currently in a position to meet expected customer demand levels in the coming quarters, we recognize that unpredictable events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could negatively impact our business, results of operations, financial condition and cash flows.

The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. The Russian invasion of Ukraine in February 2022 has led to further economic disruptions. Mounting inflationary cost pressures and recessionary fears have negatively impacted the global economy. During the third quarter of 2022, the U.S. Federal Reserve continued to aggressively address elevated inflation by increasing interest rates. The U.S. Federal Reserve increased interest rates by 75 basis points in each of its meetings held in July, September and November 2022, with an additional increase forecasted for December 2022 as inflation remains elevated. Given current market conditions, we may be unable to access the capital markets, and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.

For additional information on risks that could impact our future results, please refer to “Risk Factors” in Part II, Item 1A. of this quarterly report on Form 10-Q.

Sources of Revenue

Product revenue

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of our contracts have a single performance obligation to transfer products. Accordingly, we recognize revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. We sell our products both directly to customers and through distributors generally under agreements with payment terms typically 60 days or less.

We may record an estimated allowance, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.

27


 

Royalty and other

Our licensing contracts typically provide for royalties based on the licensee’s use of our memory technology in its currently shipping commercial products. We estimate its royalty revenue in the calendar quarter in which the licensee uses the licensed technology.  Payments are received in the subsequent quarter. We also generate revenue from licensing our technology. We recognize license fees as revenue at the point of time when the control of the license has been transferred and we have no continuing performance obligations to the customer.

Engineering services revenue

Engineering and development contracts with customers generally contain a single performance obligation that is delivered over time. Revenue is recognized using an output method that is consistent with the satisfaction of the performance obligation as a measure of progress.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the “Notes to Consolidated Financial Statements” in our annual report on Form 10-K for the year ended December 31, 2021. As of September 30, 2022, there have been no material changes to our significant accounting policies and estimates.

Reclassifications

We previously classified intangible asset amortization expense related to the developed technology and customer relationships intangibles within research and development expenses (R&D) in our condensed consolidated statements of operations and comprehensive loss. Amortization expense on the developed technology intangible asset is now classified within cost of net revenue, and amortization expense on customer relationships is now classified in selling, general and administrative expenses (SG&A). Prior period amounts have been conformed to the current period presentation. See Notes 1 and 5 to the condensed consolidated financial statements for a discussion of the reclassifications.

Results of Operations

Net Revenue

 

 

September 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

2021 to 2022

 

 

 

(dollar amounts in thousands)

 

Product -three months ended

 

$

3,060

 

 

$

1,389

 

 

$

1,671

 

 

 

120

%

Percentage of total net revenue

 

 

93

%

 

 

69

%

 

 

 

 

 

 

 

 

Product -nine months ended

 

$

10,384

 

 

$

3,016

 

 

$

7,368

 

 

 

244

%

Percentage of total net revenue

 

 

95

%

 

 

79

%

 

 

 

 

 

 

 

 

 

The following table details revenue by product category for the three and nine months ended September 30, 2022 (in thousands):

 

 

 

For the three months ended September 30,

 

 

For the nine months ended September 30,

 

 

Product category

 

2022

 

 

2021

 

 

change

 

 

2022

 

 

2021

 

 

change

 

 

Memory ICs

 

$

1,748

 

 

$

 

 

$

1,748

 

 

$

5,528

 

 

$

 

 

$

5,528

 

 

mmWave ICs

 

 

533

 

 

 

1,033

 

 

 

(500

)

 

 

1,699

 

 

 

2,651

 

 

 

(952

)

 

mmWave modules

 

 

779

 

 

 

292

 

 

 

487

 

 

 

3,139

 

 

 

292

 

 

 

2,847

 

 

mmWave other products

 

 

 

 

 

64

 

 

 

(64

)

 

 

18

 

 

 

73

 

 

 

(55

)

 

 

 

$

3,060

 

 

$

1,389

 

 

$

1,671

 

 

$

10,384

 

 

$

3,016

 

 

$

7,368

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

28


 

 

Product revenue increased for the three months ended September 30, 2022 compared with the same period of 2021 primarily due to the increase in the memory IC sales volumes due to the acquisition of this product line in December 2021 and the increase of the mmWave module sales volumes due to the roll-out of this product line in August 2021. As discussed elsewhere in this Report, for reverse-acquisition accounting purposes, Peraso Tech, was treated as the accounting acquirer, and MoSys was treated as the accounting acquiree. Accordingly, the results of operations discussed herein are a continuation of Peraso Tech’s historical financial results and exclude the results of operations of MoSys prior to December 17, 2021. The increase in memory IC sales volumes, which was due to the acquisition of this product line, resulted in a $1.7 million increase to revenue for the three months ended September 30, 2022, as compared to the prior year due to a 100% increase in sales volumes in 2022. Additionally, we began selling our mmWave module products during the second half of 2021, representing a 119% increase in sales volumes and an additional $0.5 million in revenue for the three months ended September 30, 2022. We have initiated price increases on certain of our module products in 2022. However, through September 30, 2022, we had not realized any material increase in revenue as a result of those price increases.

Product revenue increased for the nine months ended September 30, 2022 compared with the same period of 2021 primarily due to increase in the memory IC sales volumes due to the acquisition of this product line in December 2021 and the increase of mmWave module sales volumes due to the roll-out of this new product line in the second half of 2021. The increase in memory IC sales volumes resulted in a $5.5 million increase in revenues for the nine months ended September 30, 2022 as compared to prior year due to a 100% increase in sales volumes. Additionally, we began selling our mmWave module products during the second half of 2021 and realized a 100% increase in sales volumes in 2022, which contributed $2.8 million of increased revenue for the nine months ended September 30, 2022. We initiated price increases on certain of our module products in 2022. However, through September 30, 2022, we had not realized any material increase in revenue as a result of those price increases. These revenue increases were partially offset by a decrease of $1.0 million in sales of our mmWave IC products due to a 39% reduction in volumes shipped during the nine months ended September 30, 2022, compared with the same period in 2021. Although, stand-alone mmWave IC volumes decreased, shipments of our mmWave modules that include the mmWave ICs have increased, and each module we ship includes our mmWave ICs.  We began shipping modules, which include our mmWave IC in a chipset with an antenna, as it provides an integrated solution that we believe can shorten our revenue cycle by enabling our customers to accelerate time to production. In addition, we generate higher revenue from the sale of modules compared to sales of stand-alone ICs. Going forward, we expect sales of our mmWave ICs on a stand-alone basis to decline as a percentage of total product revenue, as we expect sales of our modules to be our primary source of revenue growth.

We expect revenues to increase for the remainder of 2022 and in 2023, as we expect increased sales of our mmWave products, including the benefits of price increases implemented in 2022, and will experience a full-year contribution of revenues from our memory products. We expect sales of our memory products to increase from a volume and revenue perspective over the next 12 months. However, our memory products have been in production since 2014, and, given that we have not developed new products, the long-term outlook for these products is uncertain. We have implemented modest price increases on our memory products that we expect to begin taking effect in the first half of 2023, and we expect these price increases to contribute to revenue growth in 2023. We expect sales of our mmWave modules to increase from a volume and revenue perspective over the next 12 months, as our primary sales focus is on obtaining new module customers. Our lead module customer has provided purchase orders and forecasts, which support our expected increases in volume and revenue from module shipments.  In addition, we expect meaningful contribution in 2023 from price increases that we implemented in 2022 on our module products.

.

 

 

 

September 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

2021 to 2022

 

 

 

(dollar amounts in thousands)

 

Royalty and other -three months ended

 

$

234

 

 

$

629

 

 

$

(395

)

 

 

(63

)%

Percentage of total net revenue

 

 

7

%

 

 

31

%

 

 

 

 

 

 

 

 

Royalty and other -nine months ended

 

$

597

 

 

$

800

 

 

$

(203

)

 

 

(25

)%

Percentage of total net revenue

 

 

5

%

 

 

21

%

 

 

 

 

 

 

 

 

Royalty and other includes royalty, non-recurring engineering, services and licenses revenues. The decrease in royalty and other revenue for the three and nine months ended September 30, 2022 compared with the same period of 2021 was primarily due to a decrease in non-recurring engineering services revenue related to our mmWave technology, partially offset by full three and nine-month contributions of royalty revenues from licensees of our memory technology. As the reverse acquisition occurred on December 17, 2021, the results of operations for the three and nine months ended September 30, 2021 exclude all royalty revenue from licensing of memory technology.

29


 

Cost of Net Revenue and Gross Profit

 

 

September 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

2021 to 2022

 

 

 

(dollar amounts in thousands)

 

Cost of net revenue -three months ended

 

$

2,000

 

 

$

919

 

 

$

1,081

 

 

 

118

%

Percentage of total net revenue

 

 

61

%

 

 

46

%

 

 

 

 

 

 

 

 

Cost of net revenue -nine months ended

 

$

6,747

 

 

$

1,973

 

 

$

4,774

 

 

 

242

%

Percentage of total net revenue

 

 

61

%

 

 

52

%

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

2021 to 2022

 

 

 

(dollar amounts in thousands)

 

Gross profit -three months ended

 

$

1,294

 

 

$

1,099

 

 

$

195

 

 

 

18

%

Percentage of total net revenue

 

 

39

%

 

 

54

%

 

 

 

 

 

 

 

 

Gross profit -nine months ended

 

$

4,234

 

 

$

1,843

 

 

$

2,391

 

 

 

130

%

Percentage of total net revenue

 

 

39

%

 

 

48

%

 

 

 

 

 

 

 

 

Cost of net revenue is primarily comprised of direct and indirect costs related to the sale of our products, including amortization of intangible assets and depreciation of production-related fixed assets.

Cost of net revenue increased for the three and nine months ended September 30, 2022 when compared with the same period in 2021, primarily due to increased shipment volumes of our LineSpeed and Bandwidth Engine IC and mmWave module products. Our module products have higher cost of goods sold per unit and generate lower gross profit margin than our IC products.

Gross profit increased for the three and nine months ended September 30, 2022 compared with the same period of 2021 due to the increased product shipments. The decrease in our gross profit margin for the three and nine months ended September 30, 2022 compared with the prior year periods was primarily attributable to the increased volume shipments of our mmWave modules, which carry lower gross margins than our IC products.

 Research and Development

 

 

 

September 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

2021 to 2022

 

 

 

(dollar amounts in thousands)

 

R&D -three months ended

 

$

4,509

 

 

$

2,696

 

 

$

1,813

 

 

 

67

%

Percentage of total net revenue

 

 

137

%

 

 

134

%

 

 

 

 

 

 

 

 

Research and development -nine months ended

 

$

15,636

 

 

$

8,375

 

 

$

7,261

 

 

 

87

%

Percentage of total net revenue

 

 

142

%

 

 

219

%

 

 

 

 

 

 

 

 

Our R&D expenses include costs related to the development of our products. We expense R&D costs as they are incurred.

The increase for the three months ended September 30, 2022 compared with the same period of 2021 was primarily due to the inclusion of a full three months of expenses of $0.9 million related to the former operations of MoSys, amortization of acquired intangible assets from the reverse acquisition of $0.5 million, which closed on December 17, 2021, for the three and nine months ended September 30, 2022 and recognition of $0.5 million of Canadian government refundable tax credits and wage and rent subsidies during the first nine months of 2021 that reduced operating expenses.

The increase for the nine months ended September 30, 2022 compared with the same period of 2021 was primarily due to the inclusion of a full nine months of expenses of $3.8 million related to the former operations of MoSys, amortization of acquired intangible assets from the reverse acquisition of $1.5 million, which closed on December 17, 2021, and recognition of $1.8 million of Canadian government refundable tax credits and wage and rent subsidies during the first nine months of 2021 that reduced operating expenses.

We expect that total R&D expenses will increase in 2022 compared with 2021, as we will include the operations related to MoSys and increased development of our mmWave products and technologies, including our new 5G mmWave products. In addition, we do not expect to receive any Canadian government subsidies in 2022 that would reduce our R&D expenses.  

30


 

Selling, General and Administrative

 

 

 

September 30,

 

 

Change

 

 

 

2022

 

 

2021

 

 

2021 to 2022

 

 

 

(dollar amounts in thousands)

 

SG&A -three months ended

 

$

3,353

 

 

$

1,746

 

 

$

1,607

 

 

 

92

%

Percentage of total net revenue

 

 

102

%

 

 

87

%

 

 

 

 

 

 

 

 

SG&A -nine months ended

 

$

8,938

 

 

$

4,852

 

 

$

4,086

 

 

 

84

%

Percentage of total net revenue

 

 

81

%

 

 

127

%

 

 

 

 

 

 

 

 

SG&A expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, human resources and general management and amortization of intangible assets.  

The increase for the three months ended September 30, 2022 compared with the same period of 2021 was primarily due to the inclusion of $1.4 million of expense, which represented the inclusion of a full three months of expenses related to related to the former operations of MoSys, as a result of the reverse acquisition that closed in December 2021.  The increases were partially offset by a $0.5 million decrease in costs incurred during the three months ended September 30, 2021 related to the reverse acquisition.

 

The increase for the three and nine months ended September 30, 2022 compared with the same period of 2021 was primarily due to the inclusion of $4.2 million of expense, which represented the inclusion of a full nine months of expenses related to related to the former operations of MoSys, and recognition of Canadian government wage and rent subsidies during the first nine months of 2021 that reduced operating expenses. The increases were partially offset by a $1.1 million decrease in costs incurred during the nine months ended September 30, 2021 related to the reverse acquisition.

We expect that total SG&A expenses will increase in 2022 compared with 2021, as we will include the operations related to MoSys, and, in addition, we do not expect to receive any Canadian government subsidies in 2022 that would reduce our R&D expenses.  

Interest expense

Interest expense incurred during the nine months ended September 30, 2021 related to our convertible debt and loans payable, which were repaid and/or converted into equity during 2021.

Liquidity and Capital Resources; Changes in Financial Condition

Cash Flows

As of September 30, 2022, we had cash, cash equivalents and investments of $3.9 million and working capital of $9.0 million.   

Net cash used in operating activities was $13.4 million for the first nine months of 2022, which primarily resulted from our net loss of $17.8 million and $3.1 million in net changes in assets and liabilities, partially offset by non-cash charges of $2.3 million of depreciation and amortization, $4.4 million of stock based compensation, $0.7 million of allowance for doubtful accounts and $0.1 million for other non-cash items. The changes in assets and liabilities primarily related to the timing of accounts receivable collections, purchases of inventory and other vendor payables and prepayments.

Net cash used in operating activities was $7.1 million for the first nine months of 2021, which primarily resulted from our net loss of $13.4 million and a $0.1 million other non-cash items, which was offset by non-cash charges of $3.5 million of stock-based compensation, $0.8 million of depreciation and amortization expenses, $1.5 million amortization of debt discount, and $0.6 million of accrued interest.  The changes in assets and liabilities primarily related to the timing of accounts receivable collections and other vendor payables and prepayments.

Net cash provided by investing activities of $10.4 million for the nine months ended September 30, 2022 represented $11.5 million in proceeds from maturities of short-term investments, partially offset by $0.5 million purchases of short and long-term investments and $0.6 million of purchases of property and equipment. Net cash used in investing activities for the nine months ended September 30, 2021 represented approximately $57,000 of purchases of property and equipment and $95,000 of intangible assets.

Net cash used in financing activities for the nine months ended September 30, 2022 consisted of taxes paid to net share settle equity awards.

Net cash provided by financing activities for the nine months ended September 30, 2021 consisted of net proceeds received from an unsecured loan.

31


 

Our future liquidity and capital requirements are expected to vary from quarter-to-quarter, depending on numerous factors, including:

 

level of revenue;

 

cost, timing and success of technology development efforts;

 

inventory levels, as supply chain disruption has required us to maintain higher inventory levels and place purchase orders with our suppliers longer into the future, which exposes us to additional inventory risk;

 

timing of product shipments, which may be impacted by supply chain disruptions;

 

length of billing and collection cycles, which may be impacted in the event of a global recession or economic downturn;

 

fabrication costs, including mask costs, of our ICs, currently under development;

 

variations in manufacturing yields, material lead time and costs and other manufacturing risks;

 

costs of acquiring other businesses and integrating the acquired operations; and

 

profitability of our business.

As of September 30, 2022, we had outstanding accounts receivable of $1.6 million, which included $0.7 million collectible from WeLink Communications LLC (WeLink), a customer that represented 28% of our revenue for the nine months ended September 30, 2022. During the three months ended September 30, 2022, we had $1.1 million of product shipments to WeLink for which the revenue recognition criteria under ASC 606 had not been met.  Accordingly, we deferred the cost of net revenue of $0.6 million associated with these shipments, and the amount deferred has been presented as deferred cost of net revenue in our condensed consolidated balance sheets.

Historically, we have collected all amounts due from WeLink, although generally not within contractual payment terms. As of September 30, 2022, we determined that an allowance for doubtful accounts of $0.7 million was warranted on the outstanding receivables from WeLink due to the delays in collecting from WeLink. The longer collection times have negatively impacted our liquidity and working capital.  No assurances can be given that we will be able to collect the receivables from WeLink in a timely manner, if at all. Recognition of additional bad debt expense, further delays in collecting accounts receivable or our inability to recognize the deferred cost of net revenues could have a material adverse effect on our financial condition, cash flows and results of operations.

Going Concern - Working Capital

We incurred net losses of approximately $17.8 million for the nine months ended September 30, 2022 and $10.9 million for the year ended December 31, 2021, and we had an accumulated deficit of approximately $135.0 million as of September 30, 2022.  These and prior year losses have resulted in significant negative cash flows and have required us to raise substantial amounts of additional capital. To date, we have primarily financed our operations through multiple offerings of common stock and issuance of convertible notes and loans to investors and affiliates.

We expect to continue to incur operating losses for the foreseeable future as we continue to secure new customers for and continue to invest in the development of our products, and we expect our cash expenditures to continue to exceed receipts for the foreseeable future, as our revenues will not be sufficient to offset our operating expenses.  

We will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.  As a result of our expected operating losses and cash burn for the foreseeable future and recurring losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements, there will be uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. The condensed consolidated financial statements presented in Item 1 of this Report have been prepared assuming that we will continue as a going concern, and do not include any adjustments that might result from the outcome of this uncertainty.  There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to us. We are currently seeking additional financing in order to meet our cash requirements for the foreseeable future. If the Company is unsuccessful in these efforts, it will need to implement cost reduction strategies, which could further affect

32


 

its near- and long-term business plan. These efforts may include, but are not limited to, reducing headcount and curtailing business activities. As further discussed in Note 11 to the condensed consolidated financial statements, in August 2022, we entered into an exclusive technology license and patent assignment agreement with Intel Corporation, under which we collected $3.1 million in August 2022 and expect to collect $0.4 million by early 2023. We expect this transaction to result in a reduction of operating expenses of approximately $2.7 million on annual basis.

If we were to raise additional capital through sales of our equity securities, our stockholders would suffer dilution of their equity ownership. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, prohibit us from paying dividends, repurchasing our stock or making investments, and force us to maintain specified liquidity or other ratios, any of which could harm our business, operating results and financial condition. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

 

develop or enhance our products;

 

continue to expand our product development and sales and marketing organizations;

 

acquire complementary technologies, products or businesses;

 

expand operations, in the United States or internationally;

 

hire, train and retain employees; or

 

respond to competitive pressures or unanticipated working capital requirements.

Our failure to do any of these things could seriously harm our ability to execute our business strategy and may force us to curtail our existing operations.

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements or obligations that are reasonably likely to have a material current or future effect on our financial condition, results of operations, liquidity or capital resources.

Recent Accounting Pronouncements

See Note 1 to the condensed consolidated financial statements for a discussion of recently-issued accounting pronouncements.

33


 

ITEM 4. Controls and Procedures

Disclosure Controls and Procedures. Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of September 30, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting. During the nine months ended September 30, 2022, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

The discussion of legal matters in Note 6 of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report under the heading “Legal Matters” is incorporated by reference in response to this Part II, Item 1.

ITEM 1A. Risk Factors

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. Other than as set forth below, there have been no material changes with respect to the risk factors disclosed under Item 1A of our annual report on Form 10-K for the year ended December 31, 2021, which we filed with the SEC on March 31, 2022.

We might not be able to continue as a going concern.

Our unaudited condensed consolidated financial statements as of September 30, 2022 have been prepared under the assumption that we will continue as a going concern for the next twelve months. As of September 30, 2022, we had cash, cash equivalents and investments of $3.9 million and an accumulated deficit of $135.0 million. We do not believe that our cash, cash equivalents and investments are sufficient to fund our operations for the next 12 months. We will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.  As a result of our expected operating losses and cash burn for the foreseeable future and recurring losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements, there will be uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt as to our ability to continue as a going concern. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment in us.

If we are unable to generate sustainable operating profit and sufficient cash flows, then our future success will depend on our ability to raise capital. We are seeking additional financing and evaluating financing alternatives in order to meet our cash requirements for the next 12 months. We cannot be certain that raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current stockholders may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current product development programs, cut operating costs, forego future development and other opportunities or even terminate our operations.

34


 

We have a history of losses, and we will need to raise additional capital.

We recorded net losses of approximately $17.8 million and $10.9 million for the nine months ended September 30, 2022 and year ended December 31, 2021, respectively. These and prior-year losses have resulted in significant negative cash flows. To remain competitive and expand our product offerings to customers, we will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time. Given our history of fluctuating revenues and operating losses, and the challenges we face in securing customers for our products, we cannot be certain that we will be able to achieve and maintain profitability on either a quarterly or annual basis in the future. As a result, we will need to raise additional capital to meet our cash requirements for the next 12 months, which may or may not be available to us at all or only on unfavorable terms.

We have significant accounts receivable from a significant customer and collectability is uncertain.

As of September 30, 2022, we had outstanding accounts receivable of $1.6 million, which included $0.7 million collectible from WeLink, a customer that represented 28% of our revenue for the nine months ended September 30, 2022. During the three months ended September 30, 2022, we had $1.1 million of product shipments to WeLink for which the revenue recognition criteria had not been met.  Accordingly, we deferred the cost of net revenue of $0.6 million associated with these shipments. Historically, we have collected all amounts due from WeLink, although generally not within contractual payment terms. As of September 30, 2022, we determined that an allowance for doubtful accounts of $0.7 million was warranted on certain outstanding receivables from WeLink due to the collection delays. The longer collection times have negatively impacted our liquidity and working capital.  No assurances can be given that we will be able to collect the receivables from WeLink in a timely manner, if at all. Recognition of additional bad debt expense, further delays in collecting accounts receivable or our inability to recognize the deferred cost of net revenues could have a material adverse effect on our financial condition, cash flows and results of operations

The invasion of Ukraine by Russia could negatively impact our business.

Russia’s recent military invasion of Ukraine has led to, and may lead to, additional sanctions being levied by the United States, European Union and other countries against Russia. Russia’s military invasion and the resulting sanctions have had an adverse effect on global markets. We cannot predict the progress or outcome of the situation in Ukraine, as the conflict and governmental reactions are rapidly developing and beyond our control. Prolonged unrest, intensified military activities, or more extensive sanctions impacting the region could have a material adverse effect on the global economy, and such effect could in turn have a material adverse effect on the operations, results of operations, financial condition, liquidity and business outlook of our business.  

Sustained inflation could have a material adverse effect on our business, financial condition, results of operations and liquidity.

Inflation rates in the markets in which we operate have increased and may continue to rise. Inflation over the last several months has led us to experience higher costs, including higher labor costs, wafer and other costs for materials from suppliers, and transportation costs. Our suppliers have raised their prices and may continue to raise prices, and, although we have made minimal price increases thus far, in the competitive markets in which we operate, we may not be able to make corresponding price increases to preserve our gross margins and profitability. In addition, inflationary pressures could cause customers to delay or reduce purchases of our products or delay payments to us. If inflation rates continue to rise or remain elevated for a sustained period of time, they could have a material adverse effect on our business, financial condition, results of operations and liquidity.

If our goodwill or intangible assets become impaired, we would be required to record a charge to earnings.

We review our goodwill and intangible assets for impairment when events or changes in circumstances, such as a decline in our stock price and/or market capitalization, indicate the carrying value may not be recoverable. We test goodwill for impairment at least annually. If our goodwill or intangible assets are deemed to be impaired, an impairment loss equal to the amount by which the carrying amount exceeds the fair value of the assets would be recognized. We would be required to record an impairment charge in our financial statements during the period in which any impairment of our goodwill or intangible assets is determined, which would negatively affect our results of operations.

35


 

 

ITEM 6. Exhibits

 

(a)

Exhibits

 

 

10.1*+

Technology License and Patent Assignment Agreement By and Between Intel Corporation and Peraso Inc. dated August 5, 2022

 

31.1*

Rule 13a-14 certification

 

31.2*

Rule 13a-14 certification

 

32.1**

Section 1350 certifications

 

101*

The following financial information from Peraso Inc.’s quarterly report on Form 10-Q for the period ended September 30, 2022, filed with the SEC on November 14, 2022, formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 and 2021, (ii) the Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021, (iii) the Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2022 and 2021, (iv) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021, and (v) Notes to Condensed Consolidated Financial Statements.

 

104*

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

 

 

*Filed herewith.

+ Certain schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of such omitted materials supplementally upon request by the SEC.

**Furnished herewith.

 

 

36


 

 

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

Dated: November 14, 2022

 

PERASO INC.

 

 

 

 

By:

/s/ Ronald Glibbery

 

 

Ronald Glibbery

 

 

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

By:

/s/ James W. Sullivan

 

 

James W. Sullivan

 

 

Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

 

37

 

Exhibit 10.1

 

 

 

 

Technology License and Patent Assignment Agreement
By and Between
Intel Corporation,

And

Peraso Inc.

August 5, 2022


 


 

TECHNOLOGY LICENSE AND PATENT ASSIGNMENT AGREEMENT

This TECHNOLOGY LICENSE AND PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is made and entered into as of August 5, 2022 (the “Effective Date”), by and between Intel Corporation, a Delaware corporation (“Intel”), and Peraso Inc., a Delaware corporation (“Peraso”).  

Recitals

A.Intel and Peraso desire enter into an agreement pursuant to which, among other things: (i) Intel will exclusively license from Peraso certain software and technology assets of Peraso related to Peraso’s “Stellar Intellectual Property” technology; and (ii) Intel will acquire from Peraso certain patent applications and patents owned by Peraso, in each case (i.e., (i) and (ii) of the foregoing), on the terms and conditions set forth herein.  

B.Intel and Peraso desire to make certain representations, warranties, covenants and other agreements in connection with the transactions as set forth herein.

C.In furtherance thereof, each of Intel and Peraso have adopted and approved this Agreement and, upon the terms and subject to the conditions set forth in this Agreement, have approved the transactions contemplated by this Agreement in accordance with Applicable Laws.

Agreement

NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.

DEFINITIONS

1.1

Affiliate(s)” of a person or entity means any other person or entity that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such person or entity. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person or entity, whether through the ownership of voting securities, by contract or otherwise.

1.2

Agreement” has the meaning set forth in the preamble.

1.3

Applicable Law(s)” means all applicable provisions of all statutes, laws, rules, regulations, administrative codes, ordinances, decrees, orders, decisions, injunctions, awards, judgments, permits and licenses of or from federal, state and local, or foreign governmental authorities, including regulatory authorities.

1.4

Assigned Patents” means the patents and patent applications listed in Exhibit A hereto, and any continuations, continuations-in-part, divisions, renewals for any of the foregoing, and patents and patent applications to which any such patent or applications claim priority, any patents that issue

2

 


 

from any of the foregoing, and any reissues, substitutions, extensions or reexaminations of any of the foregoing, and any foreign counterparts of the foregoing.

1.5

Claim” has the meaning set forth in Section 11.3.

1.6

Closing” has the meaning set forth in Section 5.1.

1.7

Closing Date” has the meaning set forth in Section 5.1.  

1.8

Confidential Information” means any and all non-public information, materials, data, business plans, financial information, marketing plans, reports, forecasts, technical or other commercial information that is provided by or on behalf of the Disclosing Party to the Receiving Party hereunder, and that: (i) if disclosed in writing or other tangible form, is marked by the Disclosing Party as “Confidential” or with similar legend at the time of disclosure; (ii) if disclosed orally, is reduced to writing by the Disclosing Party and marked as “Confidential” or with similar legend and thereafter delivered to the Receiving Party within thirty (30) days of its initial oral disclosure; or (iii) based on the nature of the information or the circumstances regarding its disclosure, the Receiving Party knows or reasonably should know that the Disclosing Party treats as confidential or proprietary.  

1.9

Damages” has the meaning set forth in Section 11.1.

1.10

Disclosing Party” has the meaning set forth in Section 8.1.

1.11

Effective Date” has the meaning set forth in the preamble.

1.12

Encumbrance(s)” means any lien, pledge, charge, mortgage, easement, encroachment, imperfection of title, title exception, title defect, right of possession, lease, security interest, encumbrance, adverse claim, interference, or other restriction on use arising out of any contract or restriction on transfer.

1.13

Excluded Assets” has the meaning set forth in Section 3.3.

1.14

Excluded Liabilities” has the meaning set forth in Section 3.4.

1.15

Excluded Technology” has the meaning set forth in Exhibit C hereto.

1.16

Fabulous Agreement” means that certain Professional Services Agreement, dated March 24, 2020, between Fabulous Inventions AB and Peraso’s predecessor in interest, MoSys, Inc., and any amendments or addendums thereto.

1.17

Fabulous Technology” means the Technology licensed by Peraso from Fabulous Inventions AB pursuant to the Fabulous Agreement.

1.18

Holdback” has the meaning set forth in Section 7.1.2.

3

 


 

1.19

Improvement means any Technology or other Intellectual Property Right which includes any portion, or utilizes any portion, of a component, module, product, subassembly, assembly, device, service, method or process described in or dependent on the Licensed Technology for functionality, or any derivative work which is directly related to or which develops, enhances or improves any portion of a component, module, product, subassembly, assembly, device, service, method or process described in or dependent on the Licensed Technology for functionality.

1.20

Indemnified Party” has the meaning set forth in Section 11.3.

1.21

Indemnifying Party” has the meaning set forth in Section 11.3.

1.22

Intellectual Property Rights” means all rights of the following types, which may exist or be created under the laws of any jurisdiction in the world: (i) rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, and mask works; (ii) trademark and trade name rights and similar rights; (iii) trade secret rights; (iv) patent rights and industrial property rights; and (v) other proprietary rights in intellectual property of every kind and nature.

1.23

IRS” has the meaning set forth in Section 7.2.  

1.24

Key Personnel” has the meaning set forth in Section 5.3.1(e).

1.25

Knowledge” means the actual knowledge of the Key Personnel and each of the following individuals: Gus Lignos, Dan Lewis, John Bromhead, Jim Sullivan and Mark Baumann.

1.26

Liabilities” means all debts, liabilities and obligations, whether presently in existence or arising hereafter, accrued or fixed, absolute or contingent, matured or unmatured, determined or determinable, asserted or unasserted, known or unknown, including those arising under any law, action or governmental order.

1.27

Core Patents” means U.S. Patent No. 9971567B2 and U.S. Patent No. 9529569B2.

1.28

Licensed Technology” has the meaning set forth on Exhibit B hereto.

1.29

Non-Core Patents” means all patents and patent applications making up the Assigned Patents other than the Core Patents.  

1.30

Patent Counsel” has the meaning set forth in Section 5.2.5.  

1.31

Peraso Copyrightable Materials” has the meaning set forth in Section 2.1.2.  

1.32

Person” means any natural person, company, corporation, limited liability company, general partnership, limited partnership, trust, proprietorship, joint venture, business organization or governmental entity.

1.33

Proceeding(s)” has the meaning set forth in Section 11.1.

4

 


 

1.34

Purchased Assets” has the meaning set forth in Section 3.1.  

1.35

Receiving Party” has the meaning set forth in Section 8.1.

1.36

Release Criteria” has the meaning set forth in Section 7.1.2.  

1.37

Security Incident” has the meaning set forth in Section 2.5.2.

1.38

Sublicensee(s)” has the meaning set forth in Section 2.3.1.

1.39

Sublicense Agreement(s)” has the meaning set forth in Section 2.3.2.

1.40

Technology” means unpatented inventions, ideas, trade secrets, chemical formulae, compounding instructions, processes, techniques, know-how, designs, plans, schematics, technical information, documents, records, scientific and engineering information and data, literature, plans and specifications, whether reduced to writing or otherwise, and any manifestations or embodiments thereof and any and all Intellectual Property Rights embodied therein or associated therewith.

1.41

Technology Improvements” has the meaning set forth in Section 2.6.1.

1.42

Territory” means throughout the world.

2.

LICENSED TECHNOLOGY

2.1

License Grant.  

 

2.1.1

Peraso hereby grants to Intel an unlimited, irrevocable, perpetual, non-terminable, fully paid up, royalty-free, freely transferrable (as set forth in Section 16.3 below), freely sublicensable (through multiple tiers of sublicensees), exclusive (even as to Peraso, as set forth in Section 2.2 below) right and license, under all of Peraso’s applicable Intellectual Property Rights in and to the Licensed Technology, to develop, make, make for others, have made, perform, have performed, perform for others, use, operate, sell, offer for sale, import, and export products embodying or using the Licensed Technology, and to otherwise freely commercialize and exploit the Licensed Technology in the Territory, as Intel deems fit in its sole and absolute discretion.

 

2.1.2

For purposes of clarity, the license rights granted in this Section 2.1 include the right, under Peraso’s copyright rights in and to any and all documents and/or materials making up and/or embodying the Licensed Technology (“Peraso Copyrightable Materials”), to use, execute, display, reproduce, perform, disclose, prepare derivative works of, and distribute and transmit such Peraso Copyrightable Materials (and derivative works thereof), in connection with Intel’s exercise of the license rights in the Licensed Technology set forth in Section 2.1.1 and on the same terms and conditions set forth therein.    

2.2

Exclusivity.  The license rights granted to Intel in Section 2.1 above are exclusive to Intel, even as to Peraso. Accordingly, Peraso shall not, whether directly or indirectly through third parties,

5

 


 

including without limitation, by and/or through its Affiliates, develop, create, manufacture, market, supply, distribute operate or sell in the Territory any product, service or technology that makes use of, implements or embodies any portion of the Licensed Technology or that is otherwise based on or derived from the Licensed Technology, or otherwise authorize or assist any third party in doing so.

2.3

Sublicensing.

 

2.3.1

The license rights granted in Section 2.1 above are intended to be freely sublicensable by Intel, through multiple tiers of sublicensees.  Accordingly, Intel may sublicense the license rights granted above as it deems fit in its sole and absolute discretion, including without limitation, to its Affiliates, its customers, and to its contract foundries, resellers and distributors (each such Affiliate, customer, and contract foundry, reseller or distributor, a “Sublicensee(s)”).

 

2.3.2

The terms of any sublicense or distributor or reseller agreements shall be solely between Intel and the applicable Sublicensee (“Sublicense Agreement(s)”).

2.4

Ownership.  Intel acknowledges and agrees that Peraso owns and shall retain all Intellectual Property Rights in and to the Licensed Technology (excluding, for purposes of clarity, the Assigned Patents, which upon the Closing, are and shall at all times remain the sole and exclusive property of Intel) and that, except as expressly set forth herein, Intel shall have no right or license in or to the Licensed Technology (excluding, for purposes of clarity, the Assigned Patents, which upon the Closing, are and shall at all times remain the sole and exclusive property of Intel), whether by implication, estoppel or otherwise. Intel shall not make use of the Licensed Technology (excluding, for purposes of clarity, the Assigned Patents, which upon the Closing, are and shall at all times remain the sole and exclusive property of Intel) except as expressly authorized in this Agreement.

2.5

Security and Protection of Licensed Technology.  

 

2.5.1

Peraso shall protect the Licensed Technology to at least the same degree as Peraso protects its own Confidential Information and Technology of a similar kind or nature, but in no event using less than a commercially reasonable standard of care.

 

2.5.2

Peraso will: (i) notify Intel as soon as reasonably practicable after discovering an actual breach of Peraso’s security measures with respect to the Licensed Technology, or any other unauthorized access to or use of (either actual or suspected) the Licensed Technology (each a “Security Incident”) by emailing Intel’s representative at secure@intel.com; (ii) use commercially reasonable efforts to promptly conduct corrective actions in response to any Security Incident; and (iii) promptly conduct an investigation of any Security Incident and submit an oral report of its findings to Intel immediately, to be followed by a written report as soon as reasonably practicable. Peraso will respond to any and all reasonable requests from Intel for information regarding the Security Incident, and will reasonably cooperate with Intel in connection with any incident management, including any related law enforcement activities.  To the extent Intel requests that Peraso engage in any remedial

6

 


 

 

measures or mitigation efforts other than commercially reasonable remediation measures and/or mitigation efforts, any such remedial measures or mitigation efforts will be undertaken by Peraso at Intel’s reasonable cost and expense.  

2.6

Improvements.  

 

2.6.1

Any Improvements to or on the Licensed Technology made by Peraso or Intel (including Improvements made for Peraso or Intel by their respective employees or contractors) (“Technology Improvements”) shall be owned by the party making such Technology Improvement(s).  Any Technology Improvements made by Peraso (including Technology Improvements made for Peraso by its employees or contractors) shall automatically be deemed “Licensed Technology” and shall automatically be included in the license rights granted by Peraso to Intel in Section 2.1 above, without additional charge to Intel.

 

2.6.2

Peraso shall promptly inform Intel in writing of any Technology Improvements made by or for Peraso.  Peraso shall further promptly provide to Intel all tangible and/or physical embodiments of any and all such Technology Improvements.  

2.7

Notice.  Each party shall promptly notify the other party in writing of any written third party notice, claim or other allegation received by such party that any Licensed Technology, or any portion thereof, infringes such third party’s Intellectual Property Rights, or any written third party notice, claim or allegation received by such party that the Intellectual Property Rights in the Licensed Technology are invalid or otherwise unenforceable.

2.8

Enforcement and Defense.  The parties shall have the following rights, obligations and responsibilities with respect to the enforcement and defense of the Licensed Technology:

 

2.8.1

Enforcement. Intel, at its sole cost and expense, shall have the sole and exclusive right, but not the obligation, to enforce the Licensed Technology in the Territory or to otherwise abate the infringement thereof, and to direct and control any litigation or other enforcement action.  Peraso shall cooperate with Intel, at Intel’s sole cost and expense, as is reasonably necessary in any such action brought by Intel, including without limitation, by joining in any such suit if necessary to avoid the dismissal of the suit or if Intel otherwise determines that Peraso is an indispensable party. If Intel brings legal action, Intel shall have the sole right to direct and control the prosecution of, and the right to settle and compromise such action, provided that: (i) Intel shall consider, in good faith, the interests of Peraso in so doing; and (ii) Intel shall not, without the express written consent of Peraso, settle the suit or otherwise consent to an adverse judgment in such suit that materially diminishes or detrimentally affects in any material way the rights or interests of Peraso. In the event any monetary recovery in connection with such infringement action is obtained (either by way of a settlement or a damages award), such recovery shall be solely and exclusively retained by Intel, and Peraso shall have no claim or entitlement to any such monetary recovery.  Peraso shall have no right to enforce the Licensed Technology or otherwise abate the infringement thereof unless Intel: (a) declines to take such action; and (b) consents in writing to Peraso taking such action.  

7

 


 

 

2.8.2

Defense. In the event either party receives any claim or allegation that any Licensed Technology is invalid or otherwise unenforceable or that the Licensed Technology infringes the Intellectual Property Rights of any third party, the parties shall confer in good faith with respect to defending against or responding to any such claims or allegations.

2.9

Remedies.  

 

2.9.1

The license rights granted in Section 2.1 above are intended by the parties to be perpetual in nature, and as such, are irrevocable and non-terminable, [even in the event of a breach by Intel of this Agreement.  Accordingly, in the event of a breach of this Agreement by Intel (including without limitation, any unauthorized use or misuse of the Licensed Technology by Intel), Peraso acknowledges and agrees that: (i) Peraso waives any right to terminate or attempt to terminate the license rights granted in Section 2.1 above for breach or other cause; and (ii) Peraso’s sole and exclusive remedy in connection with any such breach, other than as set forth in Section 11 below, will be for Peraso to seek injunctive relief or equitable relief against Intel so as to remediate the breach.

 

2.9.2

In the event that: (i) Peraso ceases to conduct business in the ordinary course or otherwise sells its business and Peraso’s rights and obligations under this Agreement are not assumed and performed by a third party; (ii) Peraso becomes insolvent, admits its insolvency, or admits its inability pay its debts as they become due; or (iii) Peraso files a petition for protection under Applicable Laws relating to bankruptcy or a petition in bankruptcy is filed against Peraso that is not dismissed within ninety (90) days, then notwithstanding anything to the contrary contained in this Agreement, Intel and its Affiliates shall have the right, either directly or through its Sublicensees, to use, commercialize and exploit the Licensed Technology in accordance with the terms and conditions of this Agreement.  If this Agreement is rejected by Peraso as a debtor-in-possession or a trustee under the U.S. Bankruptcy Code or any such foreign equivalent, then Intel may elect to retain its rights under Section 365(n) of the U.S. Bankruptcy Code or any foreign equivalent.  The parties intend that no bankruptcy or bankruptcy proceeding, petition or Applicable Laws will impede, delay, or otherwise prevent Intel’s use, commercialization and exploitation of the Licensed Technology in accordance with the terms and conditions of this Agreement.

 

2.9.3

The license rights granted in Section 2.1 above and the corresponding restrictions and limitations on Peraso’s use of the Licensed Technology set forth in this Section 2 shall run with the Licensed Technology and any and all associated Intellectual Property Rights.  As such, any third party that acquires from Peraso any right, title or interest in or to the Licensed Technology or any associated Intellectual Property Rights shall be subject to and bound by such license rights, restrictions and limitations.

 

2.9.4

Notwithstanding any term or provisions of this Agreement to the contrary, Intel may terminate the license rights granted in Section 2.1 above by providing written notice to Peraso of such termination, such written notice to be accompanied by a certificate signed by a duly authorized officer of Intel certifying that Intel has ceased all use of the Licensed Technology and that any and all tangible and/or physical embodiments of the Licensed

8

 


 

 

Technology have been destroyed.  The termination of the license rights granted in Section 2.1 shall: (i) not restrict or limit any rights or licenses granted by Intel to any of its customers, contract foundries, resellers or distributors prior to the effective date of termination, including the right to use and/or commercialize any product sold or distributed by Intel and/or its resellers or distributors prior to the effective date of termination, or otherwise cause Intel to take back or have returned any such products; and (ii) except to the extent relating to acts, omissions, or claims occurring or accruing prior to the effective date of termination, automatically cause Peraso’s obligations and responsibilities set forth in this Section 2 to immediately and automatically cease.    

3.

PURCHASE AND SALE OF PURCHASED ASSETS

3.1

Subject to and upon the terms and conditions of this Agreement, upon the Closing, Intel hereby acquires from Peraso, and Peraso hereby sells, transfers, conveys, assigns and delivers to Intel, all of Peraso’s right, title and interest in and to the following assets, free and clear of any and all Encumbrances (collectively, the “Purchased Assets”):

 

3.1.1

The Assigned Patents;

 

3.1.2

The Fabulous Agreement;

 

3.1.3

All income, royalties, damages, or payments due on or after the Closing Date relating to any of the foregoing assets; and

 

3.1.4

All rights, claims or choses in action arising out of occurrences before or after the Closing Date relating to any of the foregoing assets, including all pleadings, correspondence, work product, and other documents relating to any pending, threatened, or contemplated (whether currently or previously) right, claim or choses in action.

3.2

Upon the Closing, all of the right, title and interest of Peraso in and to the Purchased Assets will pass to Intel.  

3.3

For the avoidance of doubt, the Purchased Assets will not include, and Peraso will retain, all right, title and interest in all of its properties, assets and rights of any kind, whether tangible or intangible, real or personal, other than the Purchased Assets (collectively, the “Excluded Assets”).

3.4

For the avoidance of doubt, except as specifically set forth otherwise in this Agreement, Intel shall not assume or be responsible to pay, perform or discharge any Liabilities of Peraso, including without limitation, any and all Liabilities of Peraso accruing prior to the Closing Date (“Excluded Liabilities”).  

4.

NECESSARY RIGHTS

4.1

Peraso acknowledges and agrees that the purpose underlying this Agreement is to permit Intel to freely use, commercialize and exploit the Licensed Technology and/or the Assigned Patents.  Accordingly, to the extent the use, commercialization and/or exploitation of the Licensed Technology and/or the Assigned Patents (in each case solely as contemplated in this Agreement)

9

 


 

infringes, violates or misappropriates any Intellectual Property Rights owned or controlled by Peraso, then Peraso, on its own behalf and on behalf of its Affiliates, agrees never to assert such Intellectual Property Rights owned or controlled by it to prevent Intel from otherwise using, commercializing and/or exploiting the Licensed Technology and/or the Assigned Patents as contemplated by this Agreement in connection with such infringement, violation or misappropriation.  

5.

CLOSING

5.1

Closing.  The closing of the transactions contemplated hereby (the “Closing”) will take place remotely via the exchange of documents and signatures on the date of this Agreement or at such other time and place as Intel and Peraso agree upon in writing (the “Closing Date”).  

5.2

Closing Deliverables.  At the Closing, Peraso shall deliver to Intel the following:

 

5.2.1

A duly executed copy of the Patent Assignment Agreement attached hereto as Exhibit D, transferring all Peraso’s right, title and interest in and to the Assigned Patents to Intel.

 

5.2.2

A duly executed copy of the Deed of Novation attached hereto as Exhibit G with respect to the Fabulous Agreement.

 

5.2.3

A certificate signed by a duly authorized officer of Peraso certifying that Peraso has used commercially reasonable efforts to cause each Person with whom Peraso has disclosed or otherwise made available the Licensed Technology to either destroy such Licensed Technology or return it to Peraso.

 

5.2.4

Any and all tangible and/or physical embodiments of the Licensed Technology, including without limitation, all design files, instruction sets, and any other documentation, materials or other content relating to the use and/or commercialization of the Licensed Technology, including as set forth in Exhibit B, in the form and using a delivery mechanism reasonably acceptable to Intel; except as Peraso deems necessary (A) for the purpose of satisfying its obligations or exercising its rights under this Agreement, and (B) for archival and backup purposes, provided that, in each case (i.e., (A) and (B) of the foregoing), any such retained tangible and/or physical embodiments of the Licensed Technology shall be stored and maintained solely in Peraso’s redundant data archives and/or other similar systems and shall not be generally accessible by Peraso’s personnel.

 

5.2.5

Complete copies of: (i) each patent prosecution file for each of the Assigned Patents, including original granted patents, together with a list of all contacts for Peraso’s outside counsel responsible for the preparation, prosecution, and/or maintenance of any Assigned Patents (“Patent Counsel”); and (ii) all such other documents, correspondence, and information as are necessary to register, prosecute to issuance, own, enforce, maintain, or otherwise use, commercialize and exploit the Assigned Patents, in each case (i.e., (i) and (ii) of the foregoing), in Peraso’s possession or in the possession of Peraso’s Patent Counsel.  

10

 


 

 

5.2.6

Such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Intel, as may be required to give effect to this Agreement.  

5.3

Conditions to Closing.

 

5.3.1

The obligations of Intel to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Intel’s waiver, at or prior to the Closing, of each of the following conditions:

 

(a)

The representations and warranties of Peraso contained in this Agreement and in any certificate delivered pursuant hereto shall be true and correct in all material respects on and as of the Effective Date and on and as of the Closing Date with the same effect as though made at and as of such date.

 

(b)

Peraso shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement to be performed or complied with by it prior to or on the Closing Date.

 

(c)

Intel shall have received a certificate, dated as of the Closing Date and signed by a duly authorized officer of Peraso, that each of the conditions set forth in Section 5.3.1(a) and Section 5.3.1(b) have been satisfied.

 

(d)

No injunction or restraining order shall have been issued by any governmental authority, and be in effect, which restrains or prohibits any material transaction contemplated hereby.

 

(e)

Intel shall have entered into employment and/or independent contractor agreements, in each case as determined by Intel in its sole and absolute discretion, with not less than eight (8) of the Persons responsible for working with the Licensed Technology either as employees or independent contractors of Peraso set forth on Exhibit E hereto (the “Key Personnel”). Peraso hereby: (i) waives any provision of any employment agreement, independent contractor agreement, or other agreement between Peraso and any such Key Personnel that would in any way restrict, limit or impair Intel’s hiring of such Key Personnel (either as employees or independent contractors of Intel) or any tasks, roles or job responsibilities which Intel may assign to any such Key Personnel solely with respect to the Licensed Technology or the Purchased Assets as contemplated by this Agreement; and (ii) agrees never to assert against Intel or any such Key Personnel any claim or action that would in any way restrict, limit or impair Intel’s hiring of such Key Personnel (either as employees or independent contractors of Intel) solely with respect to the Licensed Technology or the Purchased Assets as contemplated in this Agreement or any tasks, roles or job responsibilities which Intel may assign to any such Key Personnel solely with respect to the Licensed Technology or the Purchased Assets as contemplated by this Agreement.

11

 


 

 

5.3.2

The obligations of Peraso to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Peraso’s waiver, at or prior to the Closing, of each of the following conditions:

 

(a)

The representations and warranties of Intel contained in this Agreement and in any certificate delivered pursuant hereto shall be true and correct in in all material respects on and as of the Effective Date and on and as of the Closing Date with the same effect as though made at and as of such date

 

(b)

Intel shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement to be performed or complied with by it prior to or on the Closing Date.

 

(c)

Peraso shall have received a certificate, dated as of the Closing Date and signed by a duly authorized officer of Intel, that each of the conditions set forth in Section 5.3.2(a) and Section 5.3.2(b) have been satisfied.

 

(d)

No injunction or restraining order shall have been issued by any governmental authority, and be in effect, which restrains or prohibits any material transaction contemplated hereby.

6.

Expenses

6.1

Each party shall be responsible for paying its own costs and expenses and for securing all consents, permits, authorizations, approvals, licenses or certificates necessary for it to discharge its responsibilities under this Agreement and to otherwise consummate the transactions contemplated by this Agreement, the Patent Assignment Agreement and the Deed of Novation.  Neither party shall have any responsibility or liability to pay or compensate any employee, agent, or independent contractor employed by or otherwise associated with the other party.

7.

CONSIDERATION

7.1

Payment.  Intel shall pay to Peraso, as the sole and exclusive payments to be paid by Intel to Peraso under this Agreement, the total amount of $3,500,000 USD, payable as follows:

 

7.1.1

At the Closing, Intel will pay to Peraso the amount of $3,062,500 USD, by wire transfer of immediately available funds to an account designed in writing by Peraso to Intel;

 

7.1.2

Following the Closing, Intel will pay to Peraso the amount of $437,500 USD (the “Holdback”) upon the satisfaction by Peraso, as mutually agreed upon by the parties in good faith, of the release criteria set forth in Exhibit F hereto (the “Release Criteria”). Intel and Peraso will work together in good faith so as to ensure that the Release Criteria is satisfied by Peraso no later than six (6) months following the Closing Date.  Intel will pay the Holdback to Peraso by wire transfer of immediately available funds to an account designated in writing by Peraso to Intel.

12

 


 

Other than in connection with Intel’s obligations under Section 11 below, if any, upon the payment by Intel of the payments set forth in this Section 7.1, Intel will have no other payment obligations of any kind to Peraso under this Agreement.  

7.2

Tax Matters.  The payments made by Intel to Peraso hereunder will be allocated in accordance with Schedule 8.2.  After the Closing, the parties will make consistent use of such allocation for all tax purposes and in all filings, declarations, and reports with the Internal Revenue Service (the “IRS”) in respect thereof, including the reports required to be filed under Section 1060 of the Internal Revenue Code.  If Intel determines that the purchase and sale of the Purchased Assets constitutes an “applicable asset acquisition” under Section 1060, Intel will prepare and deliver to Peraso within forty-five (45) days after the Closing Date such information as is necessary for Peraso to complete IRS Form 8594 for filing by Peraso with the IRS.  In any proceeding related to the determination of any tax, neither Intel nor Peraso will contend or represent that such allocation is not a correct allocation.

8.

CONFIDENTIALITY  

8.1

Confidential Information.  In performing its respective obligations under this Agreement, a party may receive the Confidential Information of the other party.  For purposes of this Section 8, a party who receives the Confidential Information of the other party will be referred to as the “Receiving Party” and the party disclosing such Confidential Information will be referred to as the “Disclosing Party.”

8.2

Restrictions on Use and Disclosure.  The Receiving Party acknowledges the highly confidential and proprietary nature of the Disclosing Party’s Confidential Information and agrees, except as expressly authorized or permitted under this Agreement: (i) to hold such Confidential Information in confidence and to take all reasonable precautions to protect such Confidential Information against unauthorized use or disclosure (including, without limitation, all precautions the Receiving Party employs with respect to its own confidential materials of like kind); (ii) not to divulge any such Confidential Information to any third person without the Disclosing Party’s prior written consent, except that the Receiving Party may disclose the Disclosing Party’s Confidential Information to its employees, contractors, agents or representatives having a bona fide need to know such Confidential Information and who are similarly bound by confidentiality and non-use obligations at least as restrictive as those set forth in this Agreement; and (iii) not to make any use whatsoever of such Confidential Information, except as necessary to exercise its rights and/or perform its obligations and responsibilities hereunder.    

8.3

Exceptions.  The confidentiality and non-use obligations imposed by this Agreement will not apply to information that, as evidenced by the Receiving Party’s contemporaneous written records: (i) was in the possession of the Receiving Party without confidentiality restriction prior to disclosure by the Disclosing Party; (ii) at or after the time of disclosure by the Disclosing Party, becomes generally available to the public through no act or omission on the part of the Receiving Party that is not expressly authorized hereunder; (iii) has come into the possession of the Receiving Party without confidentiality restriction from a third party and such third party is under no obligation to

13

 


 

maintain the confidentiality of such information; or (iv) is independently developed by the Receiving Party without use of or reference to any Confidential Information.

8.4

Judicial Order.  The Receiving Party may, without breaching or violating Section 8.2 above, further disclose the Disclosing Party’s Confidential Information to the extent the Receiving Party is compelled to do so by operation of law, government regulation, or order of a court of competent jurisdiction, provided that, the Receiving Party shall: (i) provide reasonable prior written notice of such compelled disclosure so as to permit the Disclosing Party to take action to protect its interests; (ii) provide reasonable assistance to restrict disclosure at the Disclosing Party’s expense, which may include assistance in obtaining a protective order or similar remedy; and (iii) only disclose that portion of the Confidential Information that, in the opinion of the Receiving Party’s legal counsel, it is legally compelled or otherwise required to disclose.

8.5

Confidentiality of Agreement.  The terms of this Agreement will be treated as Confidential Information pursuant to this Section 8, except that either party may disclose the terms of this Agreement: (i) pursuant to litigation between the parties to enforce, defend or interpret this Agreement; (ii) to its respective legal counsel, accountants, or other professional advisors; and (iii) as required by Applicable Law.

8.6

Return of Confidential Information.  At any time upon request of the Disclosing Party, the Receiving Party will promptly return or destroy (and certify such destruction in writing) all items and materials, including any copies, in its possession, custody, or control which contain any Confidential Information of the Disclosing Party.  All notes or other work product containing Confidential Information will be destroyed, and such destruction will be certified in writing to the Disclosing Party by an authorized representative of the Receiving Party who supervised such destruction.  Notwithstanding the foregoing, the Receiving Party may retain one (1) copy of Confidential Information for archival and back-up purposes, provided that, any such retained Confidential Information shall be stored and maintained solely in the Receiving Party’s redundant data archives and/or other similar systems and shall not be generally accessible by the Receiving Party’s personnel. For purposes of clarity, this Section 8.6 shall not be interpreted or construed as requiring that Intel return to Peraso or destroy any of the Licensed Technology.  

8.7

Confidentiality Term.  The Receiving Party’s obligations and responsibilities with respect to the use and/or disclosure of the Disclosing Party’s Confidential Information shall continue for so long as such Confidential Information does not fall within one of the exceptions set forth in Section 8.3 above.

8.8

Remedies. The Receiving Party acknowledges and agrees that due to the unique nature of the Confidential Information, there may be no adequate remedy at law for any breach of its obligations hereunder, and that any such breach may result in irreparable harm to the Disclosing Party. Accordingly, upon any such breach or any threat thereof, the Disclosing Party shall be entitled to seek appropriate equitable relief (without the posting of any bond) in addition to whatever remedies it might have at law.  The Receiving Party will promptly notify the Disclosing Party in writing upon its knowledge of the occurrence of any unauthorized release or other breach of the Disclosing Party’s Confidential Information.  

14

 


 

9.

REPRESENTATIONS AND WARRANTIES OF PERASO

Peraso represents and warrants to Intel as follows:

9.1

Organization, Standing and Power.  Peraso is a corporation duly organized, validly existing, and in good standing under the laws of Delaware.

9.2

Authority.  Peraso has full power and authority to enter into and perform all of its obligations and responsibilities under this Agreement, the Patent Assignment Agreement and the Deed of Novation.

9.3

Binding Obligation. This Agreement, the Patent Assignment Agreement and the Deed of Novation is, or when executed by Peraso will be, legal, valid, and binding obligations of Peraso, enforceable against Peraso in accordance with their respective terms, except as enforceability may be limited by bankruptcy, insolvency, or other similar laws of general application or by general principles of equity.  

9.4

No Conflicts. The execution and delivery by Peraso of this Agreement, the Patent Assignment Agreement and the Deed of Novation do not, and the consummation of the transactions contemplated hereby and thereby, will not and does not:

 

9.4.1

Conflict with Peraso’s articles of incorporation, bylaws, articles of organization, operating agreement, certificate of limited partnership, partnership agreement, trust agreement, or other similar organizational documents, in any material respect;

 

9.4.2

Breach any agreement to which Peraso is a party, or give any Person the right to accelerate any material obligation of Peraso;

 

9.4.3

Violate any law, judgment, or order to which Peraso is subject, in any material respect; or

 

9.4.4

Require the consent, authorization, or approval of any Person, including but not limited to any governmental body, except as to which the failure to obtain such consents, authorizations or approvals would not reasonably be expected to have a material adverse effect on Peraso’s ability to consummate the transactions contemplated by this Agreement, the Patent Assignment Agreement and the Deed of Novation.  

9.5

Title and Rights.  

 

9.5.1

Peraso is the sole and exclusive owner of the Licensed Technology and the Purchased Assets and owns good and transferrable title to the Licensed Technology and the Purchased Assets, free and clear of any and all Encumbrances.  All inventors and/or other Peraso employees or independent contractors that contributed to the development and/or creation of the Licensed Technology or the inventions described in the Assigned Patents have assigned their Intellectual Property Rights in and to the Licensed Technology and the Assigned Patents to Peraso.  

15

 


 

 

9.5.2

Upon the consummation of the transactions contemplated by this Agreement, Intel will acquire good, valid and marketable title to the Purchased Assets, free and clear of any and all Encumbrances.

 

9.5.3

Peraso is not currently party to, nor has Peraso granted, any licenses, covenants, releases, waivers, immunities, remedy limitations or other rights specific to or directly involving the Licensed Technology and/or the Licensed-Back Patents, or to Peraso’s Knowledge, the Non-Core Patents.

 

9.5.4

Peraso has not and will not enter into an agreement that will subject Intel to any covenant not to sue or similar restrictions on its enforcement of any Intellectual Property Rights in and to the Licensed Technology and/or the Core Patents, or to Peraso’s Knowledge, the Non-Core Patents, or on its enjoyment or use of the Licensed Technology and/or the Core Patents, or to Peraso’s Knowledge, the Non-Core Patents, as a result of the transactions contemplated by this Agreement or any prior transaction related to the Licensed Technology and/or the Assigned Patents.

9.6

Compliance with Legal Requirements.  Peraso is in compliance in all material respects with Applicable Laws that is applicable to Peraso and that is or was applicable to Peraso’s conduct, acts, or omissions since January 1, 2015 with respect to the Licensed Technology or since October 22, 2020 with respect to the Purchased Assets.  Peraso has not received any written notice or other written communication from any Person regarding any actual, alleged, possible or potential violation of, or failure to so comply with, any such Applicable Laws.  

9.7

Solvency.  Peraso is not entering into this Agreement with the actual intent to hinder, delay, or defraud any creditor of Peraso.    

9.8

Intellectual Property.  

 

9.8.1

(i) Schedule 10.8.1 contains a correct, current and complete list of all patents and patent applications included in the Assigned Patents, specifying as to each, as applicable, the title, the record owner, the jurisdiction in which it has been issued or filed, the patent number or application serial or publication number, and the issue or application filing date; and (ii) all filing, maintenance, and annuity fees related to the Assigned Patents are up to date and paid to the U.S. Patent and Trademark Office and other relevant international and foreign governmental authorities and authorized registrars, and all such patents and patent applications are in good standing.  

 

9.8.2

All of the Intellectual Property Rights in and/or to the Licensed Technology are valid, subsisting, and enforceable.

 

9.8.3

(i) The Core Patents, and to Peraso’s Knowledge, the Non-Core Patents, are valid, subsisting, and enforceable, in all applicable jurisdictions; and (ii) prior to their application, the claimed inventions of any Core Patents, and to Peraso’s Knowledge, any Non-Core Patents, have not been disclosed by Peraso to any third party, including without limitation, Peraso’s Affiliates, partners, vendors, and potential or actual customers, in each case, in

16

 


 

 

any manner that would destroy their novelty.  Neither Peraso nor any of its representatives have engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate or hinder the enforcement of the Core Patents, or to Peraso’s Knowledge, the Non-Core Patents.

 

9.8.4

The Licensed Technology and the inventions claimed in the Core Patents do not, and their use and/or commercialization by Intel as contemplated in this Agreement will not, infringe, violate or misappropriate the Intellectual Property Rights or other proprietary rights of any Person.

 

9.8.5

To Peraso’s Knowledge, the inventions claimed in the Non-Core Patents do not, and their use and/or commercialization by Intel as contemplated in this Agreement will not, infringe, violate or misappropriate the Intellectual Property Rights or other proprietary rights of any Person.

 

9.8.6

There are no actions (including any U.S. Patent Trial and Appeal Board proceedings) settled, pending, or to the Knowledge of Peraso, threatened in writing (including in the form of offers to obtain a license): (i) by Peraso alleging any infringement, misappropriation, or other violation of: (a) the Intellectual Property Rights in and to the Licensed Technology; or (b) the Assigned Patents; or (ii) by a third party against Peraso challenging the validity, patentability, enforceability, issuance, or ownership of: (a) the Intellectual Property Rights in and to the Licensed Technology; or (b) the Assigned Patents.

 

9.8.7

Peraso is not now, and has never been, a member or promoter of, or a contributor to, any industry standards body or any similar organization that could reasonably be expected to require or obligate Peraso to: (i) grant or offer to any other third party any license or right to any of the Assigned Patents; or (ii) grant or offer to any other third party any license or other right to any of the Licensed Technology that is inconsistent with or contrary to the license rights granted by Peraso to Intel in this Agreement.

 

9.8.8

No government funding, facilities of a university or college, or other educational institution or research center, or funding from third parties, was used in the development of the Licensed Technology or in the development of any invention claimed in the Core Patents.

 

9.8.9

To the Knowledge of Peraso, no government funding, facilities of a university or college, or other educational institution or research center, or funding from third parties, was used in the development of any inventions claimed in the Non-Core Patents.    

9.9

No Other Representations and Warranties by Intel.  Peraso acknowledges and agrees that: (i) neither Intel nor any person acting on behalf of Intel is making any representations or warranties whatsoever, express or implied, beyond those expressly given by Intel in Section 10 of this Agreement; and (ii) it has not been induced by, or relied upon, any representations, warranties or statements (written or oral), whether express or implied, made by Intel that are not expressly set forth in Section 10 of this Agreement.        

17

 


 

10.

REPRESENTATIONS AND WARRANTIES OF INTEL

Intel represents and warrants to Peraso as follows:

 

10.1

Organization, Standing and Power.  Intel is a corporation duly organized, validly existing, and in good standing under the laws of the State of Delaware.

10.2

Authority.  Intel has all requisite power and authority to enter into this Agreement and to consummate the transactions contemplated by this Agreement, the Patent Assignment Agreement and the Deed of Novation.

10.3

Binding Obligation.  This Agreement, the Patent Assignment Agreement and the Deed of Novation are valid and binding obligations of Intel, enforceable against Intel in accordance with their respective terms, except as enforceability may be limited by bankruptcy, insolvency, or other similar laws of general application or by general principles of equity.

10.4

No Conflicts.  The execution and delivery by Intel of this Agreement, the Patent Assignment Agreement and the Deed of Novation does not, and the consummation of the transactions contemplated hereby and thereby will not:

 

10.4.1

Conflict with Intel’s articles of organization, operating agreement or other similar organizational documents, in any material respect;

 

10.4.2

Breach of any agreement to which Intel is a party, or give any Person the right to accelerate any material obligation of Intel;

 

10.4.3

Violate any law, judgment or order to which Intel is subject, in any material respect; or

 

10.4.4

Require the consent, authorization, or approval of any Person, including but not limited to any governmental body, except as to which the failure to obtain such consents, authorizations or approvals would not reasonably be expected to have a material adverse effect on Intel’s ability to consummate the transactions contemplated by this Agreement, the Patent Assignment Agreement and the Deed of Novation.

10.5

No Other Representations and Warranties by Peraso.  Intel acknowledges and agrees that: (i) neither Peraso nor any person acting on behalf of Peraso is making any representations or warranties whatsoever, express or implied, beyond those expressly given by Peraso in Section 9 of this Agreement; and (ii) it has not been induced by, or relied upon, any representations, warranties or statements (written or oral), whether express or implied, made by Peraso that are not expressly set forth in Section 9 of this Agreement.        

11.

INDEMNIFICATION

11.1

By Peraso.  Peraso will defend, indemnify, and hold harmless Intel, its Affiliates, successors and assigns, and the officers, directors, employees, agents and representatives of the foregoing, for, from and against, any and all damages, losses, liabilities, claims, fines, penalties and expenses (including costs of investigation and defense and reasonable and documented out-of-pocket outside

18

 


 

attorneys’ fees), whether or not involving a third party claim (collectively, “Damages”), and any and all proceedings, actions, arbitrations, audits, hearings, investigations and suits, whether civil, criminal, administrative, investigative or informal, commenced, brought, conducted or heard by or before, or otherwise involving, any court, administrative agency, or other governmental body, or any arbitrator (collectively, “Proceeding(s)”), to the extent such Damages or Proceedings result from or arise out of: (i) any breach of Peraso’s representations, warranties, covenants, agreements or other obligations under this Agreement, the Patent Assignment Agreement or the Deed of Novation; (ii) the ownership or use of the Excluded Assets; or (iii) any Excluded Liabilities.  Notwithstanding the preceding sentence, Intel acknowledges and agrees that Peraso will have no obligations or liability under this Section 11.1 if any such Damages or Proceedings would not have accrued but for: (a) an Intel Infringement; (b) the use of the Licensed Technology by Intel other than as authorized in this Agreement; or (c) the material breach by Intel of this Agreement.

11.2

By Intel.  Intel will defend Peraso and Peraso’s Affiliates, successors and assigns, and the officers, directors, employees, agents and representatives of the foregoing against any third party claim alleging that any modifications or changes by Intel to the Licensed Technology infringe, violate or misappropriate the Intellectual Property Rights of any third party (an “Intel Infringement”), and will pay the amount of any adverse final judgment or settlement entered into by Intel with respect to any such claim.  For purposes of clarity and subject to Section 11.3 below, the foregoing obligation shall include the payment by Intel of all reasonable third party costs of defense incurred by Peraso in connection with any such claim. Notwithstanding this Section 11.2, Peraso acknowledges and agrees that: (i) Intel will have no obligations or liability pursuant to this Section 11.2 unless the third party claim would not have accrued but for Intel’s modification or change to the Licensed Technology; and (ii) nothing in this Section 11.2 shall limit or relieve Peraso of its indemnity obligations set forth in Section 11.1 above.       

11.3

Indemnification Procedure. A party seeking indemnity hereunder (the “Indemnified Party”) shall promptly notify the party from whom indemnity is being sought (the “Indemnifying Party”) of the claim or suit for which the Indemnified Party is seeking indemnity (a “Claim”), provided that, the failure of the Indemnified Party to promptly notify the Indemnifying Party of the Claim will not relieve the Indemnifying Party of its duties under this Section 11 unless the Indemnifying Party is materially prejudiced by the delay.  The Indemnifying Party will assume exclusive control of the defense and settlement (including all decisions relating to litigation, defense and appeal) of any such Claim; provided that, without the Indemnified Party’s prior written consent, not to be unreasonably refused, withheld, conditioned or delayed, the Indemnifying Party may not settle such Claim in any manner that: (i) does not result in a full and complete release in favor of the Indemnified Party; (ii) would require payment by the Indemnified Party, unless fully indemnified hereunder; or (iii) require any affirmative conduct (other than a payment for which the Indemnified Party is fully indemnified hereunder) or an admission of liability on the part of the Indemnified Party. The Indemnified Party will reasonably cooperate with the Indemnifying Party, at the Indemnifying Party’s cost and expense, in its defense of the Claim.  The Indemnified Party may participate in, but not control, the defense of the Claim using attorneys of its choice and at its sole cost and expense.

11.4

Intentionally Omitted.

19

 


 

12.

LIMITATION OF LIABILITY

12.1

EXCEPT FOR IN CONNECTION WITH A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 11 ABOVE OR A BREACH BY A PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER SECTION 8 ABOVE, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE UNDER THIS AGREEMENT FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES OF ANY KIND ARISING OUT OF OR RELATING IN ANY WAY TO THIS AGREEMENT, NO MATTER THE CAUSE OF ACTION OR THEORY OF LIABILITY UNDER WHICH SUCH DAMAGES ARE SOUGHT (WHETHER FOR BREACH OF CONTRACT, TORT, OR STRICT LIABILITY), AND REGARDLESS OF WHETHER SUCH PARTY HAS BEEN ADVISED OF OR OTHERWISE HAD REASON TO KNOW OF THE POSSIBILITY OF SUCH DAMAGES.

12.2

THE PARTIES ACKNOWLEDGE AND AGREE THAT: (i) IN NO EVENT SHALL PERASO’S TOTAL AGGREGATE LIABILITY FOR DAMAGES UNDER THIS AGREEMENT EXCEED THE TOTAL AMOUNT OF $10 MILLION USD; AND (ii) IN NO EVENT SHALL INTEL’S TOTAL AGGREGATE LIABILITY FOR DAMAGES UNDER THIS AGREEMENT EXCEED THE TOTAL AMOUNT OF $10 MILLION USD, PROVIDED THAT, THE FOREGOING SHALL NOT RESTRICT OR LIMIT INTEL’S LIABILITY IN CONNECTION WITH OR ARISING OUT OF: (a) ANY INTEL INFRINGEMENT; OR (b) INTEL’S UNAUTHORIZED USE OF THE LICENSED TECHNOLOGY.  

12.3

THE DISCLAIMERS AND LIMITATIONS OF LIABILITY SET FORTH IN THIS AGREEMENT SHALL CONTINUE TO APPLY NOTWITHSTANDING THE FAILURE OF ANY ESSENTIAL PURPOSE.

13.

FURTHER ASSURANCES

13.1

The parties will cooperate reasonably with each other in connection with any steps required to be taken as part of their respective obligations under this Agreement, and will: (i) furnish upon request to each other such further information; (ii) execute and deliver to each other such other documents; and (iii) do such other acts and things, all as the other party may reasonably request for the purpose of carrying out the intent of this Agreement and the transactions contemplated by this Agreement.

14.

INSURANCE

14.1

Peraso will obtain and maintain for a period of five (5) years following the Closing Date, commercial general liability insurance, product liability insurance and public liability insurance, insuring against all liability of Peraso, including products-completed operations hazards coverage, the broadest available form of contractual liability coverage, and a global liability insurance endorsement in those geographical areas where Peraso conducts business.  The required insurance under this Section 14 shall have limits of liability not less than $2,000,000 USD on an occurrence basis and $5,000,000 USD on an aggregate basis.

14.2

Upon request, Peraso shall furnish Intel with certificates evidencing the required coverage.  Failure on the part of Intel to demand such certificate or to identify deficiencies in the certificates shall not

20

 


 

be construed as a waiver of Peraso’s obligation to maintain the required insurance.  Peraso shall provide Intel thirty (30) days’ prior written notice of any change or cancellation to its insurance required by Section 14.1.

15.

AUDITS

15.1

Intel will have the right, using a third party auditor, to audit and inspect, during Peraso’s normal business hours and in such a manner so as to minimize any material disruption to Peraso’s business, Peraso’s books and records for the purposes of assessing and evaluating Peraso’s compliance with its obligations and responsibilities under this Agreement. Peraso shall reasonably cooperate with Intel in connection with any such audit or inspection. Intel acknowledges and agrees that: (i) Intel’s written request for any such audit and inspection will be submitted to Peraso at least fifteen (15) business days prior to the specified audit date; (ii) Intel will have no right to audit the Audited Party more than twice during any calendar year period; (iii) (a) such third party auditor shall be reasonably acceptable to Peraso; and (b) such third party auditor shall enter into a non-disclosure agreement with Peraso that is reasonably acceptable to Peraso. All information disclosed to or observed by Intel in connection with any such audit shall automatically be deemed Peraso’s Confidential Information hereunder. Any such audit and inspection shall be conducted at Intel’s cost and expense.

16.

MISCELLANEOUS

16.1

Independent Contractors. Each party is an independent business and neither party has or will have any power, right or authority, nor will either party represent that it has any power, right or authority, to bind the other party or to assume or to create any obligation or responsibility, express or implied, on behalf of the other party.  Nothing stated in this Agreement shall be construed as constituting a partnership or franchise agreement between Intel and Peraso or as creating relationships of employer and employee, master and servant, or principal and agent between the parties. Except as provided otherwise in this Agreement, each party has the sole discretion to determine its methods of operation, its accounting practices, the types and amounts of insurance it carries, its personnel practices, its advertising and promotional practices, and its customers.

16.2

Entire Agreement.  This Agreement, the Patent Assignment Agreement and the Deed of Novation, including without limitation, any exhibits or schedules hereto, constitutes the full and complete understanding and agreement of the parties with respect to the subject matter covered herein and supersedes all prior oral or written understandings and agreements with respect thereto.

16.3

Assignment.

 

16.3.1

Neither party may assign its rights or delegate its obligations under this Agreement without the prior written consent of the other party, such consent not to be unreasonably refused, withheld, conditioned or delayed.

 

16.3.2

Notwithstanding Section 16.3.1 above, each party shall have the right to freely assign this Agreement, whether by merger, sale of assets, sale of stock, reorganization or otherwise,

21

 


 

 

to any Affiliate of such party or to any successor to such party’s business or assets to which this Agreement relates.

 

16.3.3

Notwithstanding Section 16.3.2 above, in the event that Peraso assigns this Agreement pursuant to Section 16.3.2 to a competitor of Intel listed on Exhibit H hereto, as a consequence of such assignment, Peraso shall be deemed, automatically and without any further action on the part of the parties, to have irrevocably and without further consideration assigned, transferred and conveyed to Intel (and effective upon such assignment, Peraso does hereby assign, transfer and convey to Intel) any and all of Peraso’s right, title and interest in and to the Licensed Technology, provided that: (i) Peraso shall provide written notice of such assignment to Intel prior to such assignment becoming effective; and (ii) Peraso’s assignee or successor in interest shall, for a period of two (2) years following the effective date of such assignment, be liable to Intel for Peraso’s representations and warranties in Section 9 above (including any breach thereof, whether or not prior to or following the effective date of such assignment) and Peraso’s indemnity obligations set forth in Section 11, and Peraso shall deliver to Intel a certificate signed by a duly authorized officer of Peraso’s assignee or successor in interest certifying that such assignee or successor in interest is and will be liable to Intel accordingly.  

Any assignment or delegation in violation of this Section 16.3 shall be void and of no effect.  

 

16.4

Waiver or Modification.  No waiver of any of the provisions of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar, nor shall any waiver constitute a continuing waiver.  Any waiver, modification or amendment of any provision of this Agreement shall be effective only if in writing in a document that specifically refers to this Agreement and such document is signed by both of the parties hereto.

16.5

Governing Law; Jurisdiction.  This Agreement shall be governed by and construed in accordance with the laws of the State of California, USA, without reference to conflict of law principles.  The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.  All disputes hereunder shall be resolved in the federal courts of the United States or the courts of the State of California in each case located in Santa Clara County.  The parties consent to the jurisdiction of such courts, agree to accept service of process by mail, and waive any jurisdictional or venue defenses otherwise available.

16.6

Attorneys’ Fees.  If any arbitration, action, suit or proceeding is instituted to interpret, enforce, or rescind this Agreement, or otherwise in connection with the subject matter of this Agreement, the prevailing party on a claim will be entitled to recover with respect to the claim, in addition to any other relief awarded, the prevailing party’s reasonable and documented out-of-pocket outside attorneys’ fees and other fees, costs, and expenses of every kind incurred in connection with the arbitration, action, suit or proceeding, any appeal or petition for review, the collection of any award, or the enforcement of any order, as determined by the arbitrator or court.

22

 


 

16.7

Notices.  All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given when delivered personally to the recipient or when sent by email upon electronic confirmation thereof, or three (3) business days after being sent to the recipient by reputable international courier service (charges prepaid) at the appropriate address indicated below or to such other address as may be given in a notice sent to all parties hereto:

If to Intel:

Intel Corporation

101 Innovation Drive

San Jose, CA 95134

Attn.: Mike Fitton

Email:

 

With a copy (which copy shall not constitute notice) to:

 

Stoel Rives LLP

760 SW Ninth Ave, Suite 3000

Portland, OR 97205

Attn.: Matthew R. Wilmot

Email:

 

 

If to Peraso:

2309 Bering Drive

San Jose, CA 95131

Attn.: Ronald Glibbery

Email:

 

With a copy (which copy shall not constitute notice) to:

 

Mitchell Silberberg & Knupp LLP

437 Madison Ave., 25th Floor

New York, NY 10022

Attn.: Blake Baron

Email:

 

16.8

Force Majeure.  Any delay or failure of a party to perform its obligations under this Agreement, other than Intel’s payment obligations pursuant to Section 7.1, will be excused to the extent that the delay or failure was caused directly by an event beyond that party’s reasonable control, without that party’s fault or negligence, and which by the event’s nature could not have been foreseen or if it could have been foreseen, was unavoidable, including natural disasters (such as earthquake, fire, or flood), war, riot, acts of terrorism, pandemics, or acts of civil or military authorities. The affected party will give prompt notice of the force majeure event and the anticipated duration of the event, and will use diligent efforts to minimize the effects of the force majeure event and to end the force majeure event and resume full performance under this Agreement.

23

 


 

16.9

Severability.  If any provision of this Agreement is held illegal, invalid or unenforceable by a court of competent jurisdiction, that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable.

16.10

Product of Negotiation.  This Agreement is the product of the negotiation of the parties.  For convenience, this Agreement has been drafted initially in substantial part by legal counsel for one of the parties, but by agreement of the parties, this Agreement will be deemed to have been drafted by all parties jointly, and any ambiguity herein will not be construed for or against any party by virtue of the identity of the drafter or otherwise.

16.11

Counterparts.  This Agreement may be executed in counterparts by facsimile or e-mail, each of which will be deemed an original and all of which together will constitute one and the same instrument.

16.12

Headings.  The headings contained in this Agreement have been inserted for convenience of reference only and shall not modify, define, expand or limit any of the provisions of this Agreement.

 

[signature page follows]

 

24

 


 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.

INTEL CORPORATION

 

Intel

By: /s/ Sandra Rivera________________
Name: Sandra Rivera
Title: EVP & GM, Data Center & AI Group

 

 

 

PERASO INC.  

Peraso

By: /s/ Ron Glibbery________________  
Name: Ron Glibbery
Title: CEO

 

 

 

 

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

RULE 13a-14 OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, Ronald Glibbery, certify that:

 

 

1.

I have reviewed this quarterly report on Form 10-Q of Peraso Inc. for the period ended September 30, 2022;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: November 14, 2022

 

 

 

/s/ Ronald Glibbery

 

Ronald Glibbery

 

Chief Executive Officer

(Principal Executive Officer)

 

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

RULE 13a-14 OF THE SECURITIES EXCHANGE ACT OF 1934

 

I, James W. Sullivan, certify that:

 

 

1.

I have reviewed this quarterly report on Form 10-Q of Peraso Inc. for the period ended September 30, 2022;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: November 14, 2022

 

 

 

/s/ James W. Sullivan

 

James W. Sullivan

 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

Exhibit 32.1

 

CERTIFICATION OF CEO AND CFO FURNISHED PURSUANT TO

18 U.S.C. § 1350,

AS ADOPTED PURSUANT TO

§ 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report on Form 10-Q of Peraso Inc. (the “Company”) for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Ronald Glibbery, Chief Executive Officer of the Company, and James W. Sullivan, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Ronald Glibbery

 

Ronald Glibbery

 

Chief Executive Officer

(Principal Executive Officer)

 

November 14, 2022

 

 

 

/s/ James W. Sullivan

 

James W. Sullivan

 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

November 14, 2022

 

This certification accompanies this Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, or otherwise required, be deemed filed by the Company for purposes of § 18 of the Securities Exchange Act of 1934, as amended.